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PRECISION DRUG DELIVERY FOR  
VANCOMYCIN EFFICACY AND SAFETY IN  
CRITICALLY ILL PATIENTS 
 
Vancomycin is the most commonly prescribed antibiotic for hospitalized patients. 
Despite this fact and decades of clinical use, clinicians remain challenged to meet dosing 
targets of this narrow therapeutic index drug as well as minimize the risks of therapy, 
primarily nephrotoxicity. These concerns are magnified in critically ill patients given 
their severity. Accordingly, in a series of five clinical studies, we sought to identify 
optimal methods of vancomycin administration in critically ill patients to maximize 
efficacy and minimize nephrotoxicity via three techniques: use of continuous versus 
intermittent infusion, use of first-dose pharmacokinetic calculations to guide dosing, and 
use of loading doses. (1) To identify the landscape in which vancomycin is being used, 
we surveyed critical care pharmacists on self-reported vancomycin dosing practices. 
Ninety four percent (94.2%) of pharmacists reported rarely using continuous infusions 
and 89.2% rarely using first-dose pharmacokinetic evaluation. Loading doses were more 
commonly used, but rationale for not using included lack of evidence and concern for 
acute kidney injury (AKI). (2) Given this hesitation by clinicians, we performed a 
retrospective cohort study of 449 critically ill patients with confirmed methicillin-
resistant Staphylococcus aureus (MRSA) pneumonia and/or bacteremia to test the 
association of a loading dose of vancomycin (≥ 20 mg/kg) with clinical failure. While we 
found no difference in clinical failure with use of a loading dose versus not, we also 
found no difference in AKI. (3) Given that few clinicians reported using first-dose 
pharmacokinetic evaluation to guide dosing, we performed a retrospective cohort study of 
66 critically ill patients to test if first-dose pharmacokinetic evaluation was associated 
with greater area-under-the-curve (AUC) target attainment at steady state. Indeed, first-
dose pharmacokinetic evaluation increased AUC target attainment to 58.6% compared to 
32.4% (p=0.033) in those patients who received empiric dosing. (4) Method of infusion 
may also impact AKI risk in critically ill patients. We performed a systematic review and 
meta-analysis of vancomycin continuous versus intermittent infusion in critically ill 
patients. Eleven studies were identified which evaluated 2,123 patients. The risk of AKI 
was found to be significantly reduced in continuous compared to intermittent infusion: 
odds ratio 0.47 [95% confidence interval (CI) 0.34-0.65]. Additionally, continuous 
infusions were associated with 2.63 greater odds (95% CI 1.52-4.57) of pharmacokinetic 
target attainment compared to intermittent infusion. (5) In order to build from the theme 
that continuous infusions offer more precise dosing at a lower risk of AKI, we conducted 
a prospective observational study of 50 critically ill patients receiving continuous 
infusion vancomycin that consisted of 239 dosing events and 124 vancomycin 
concentrations. A population pharmacokinetic model was constructed to guide further 
precision dosing in future studies of continuous infusion vancomycin. These findings 
support further investigation of early pharmacokinetic evaluation and use of continuous 
infusions to maximize the precision of vancomycin delivery to critically ill patients and 
minimize the risk of AKI. Additionally, this work’s blueprint provides an approach for 
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1.1 Epidemiology of MRSA Infection and Vancomycin Use in Critically Ill Patients  
Vancomycin is the most commonly prescribed antibiotic for hospitalized patients 
in the United States, with reports demonstrating increasing use over time.1-4 Using 
estimates of 36.5 million hospital stays annually in the United States,5 and approximately 
100 days of therapy per 1000 patient-days,3,4 it has been estimated that over 3 million 
patients receive vancomycin every year in the United States alone.6   
Vancomycin is primarily used to treat Staphylococcus aureus, particularly 
methicillin-resistant Staphylococcus aureus (MRSA). MRSA is responsible for a wide 
variety of infections in hospitalized patients, including bloodstream infections, 
pneumonia, device-related infections, skin and soft tissue infection, and others.7 In a 
nationwide surveillance study of United States hospitals over a seven year period, 
Staphylococcus aureus was responsible for 20% of nosocomial bloodstream infections, 
with an alarming increase in MRSA isolates more than doubling from 22% to 57% over 
the period from 1995-2001.8 In critically ill patients, MRSA bacteremia was associated 
with significantly higher attributable mortality compared to methicillin-sensitive 
Staphylococcus aureus (MSSA).9 S. aureus is isolated in approximately one out of every 
five cases of ventilator-associated pneumonia, with approximately 56% MRSA isolates.10  
Vancomycin was approved by the Food and Drug Administration (FDA) in 
1958,11 yet despite additional antimicrobials garnering FDA approval, it remains one of 
the most commonly used antibiotics for MRSA, particularly in critically ill patients. A 
tricyclic glycopeptide, vancomycin is bactericidal by binding to D-alanyl D-alanine, 
which subsequently inhibits synthesis and polymerization of N-acetylmuramic acid and 






national guidelines for a variety of conditions impacting critically ill patients, it remains 
as a primary recommendation for empiric or definitive therapy for several conditions 
when MRSA infection is suspected or confirmed, including: sepsis,13 pneumonia,14 
meningitis,15 catheter-associated bloodstream infections,16 intra-abdominal infections,17 
neutropenic fever,18 endocarditis,19 and skin and soft tissue infections,20 among others.  
Other potential antimicrobials against MRSA have known limitations that may limit use. 
Daptomycin is inactivated by pulmonary surfactant thus not suitable for treating 
pneumonia,21 a common source of infection on the differential diagnosis for critically ill 
patients with sepsis and unknown foci of infection. Limited data, particularly randomized 
controlled trials, exist for ceftaroline in the above-mentioned conditions. Linezolid has 
been compared to vancomycin, but meta-analyses suggest no benefit of linezolid in terms 
of mortality, clinical response, or safety.22 In addition, the direct drug costs of these 
therapies often far exceed vancomycin. Antimicrobial stewardship concerns have 
curtailed use of other antibiotics against MRSA given limited alternative therapeutic 
options available for widespread use against MRSA should vancomycin lose sufficient 
activity against MRSA to be used for empiric therapy. As such, despite the challenges of 
using vancomycin for MRSA infections, it remains the most common choice for empiric 
or definitive antibiotic therapy for MRSA in most centers in the United States healthcare 
system.  
1.2 Need for Precision Vancomycin Dosing in Critically Ill Patients 
Despite FDA approval for over 50 years, active investigation continues into the 
optimal dosing, monitoring, and administration strategies for vancomycin, as evidenced 






(AUC)-based dosing, a paradigm shift in how vancomycin is monitored in the clinical 
setting.23 In particular, critically ill patients have arguably the greatest need for precision 
dosing of vancomycin for several reasons. First, due to life-threatening infections present 
in the intensive care unit (ICU) patient population, rapid and sustained attainment of 
pharmacokinetic/pharmacodynamic (PK/PD) targets with antimicrobials likely offers 
greater benefit in critically ill patients compared to less ill patient populations. Second, 
vancomycin is already a known narrow therapeutic index drug, and critically ill patients 
are known to have alterations impacting hydrophilic antibiotics such as vancomycin 
including altered volumes of distribution (Vd) and clearance (CL).24 Finally, patients in 
the ICU have multiple non-modifiable risk factors for acute kidney injury (AKI), and 
severity of illness is an acknowledged risk factor for vancomycin nephrotoxicity.25 In 
short, critically ill patients have the most to gain from precision dosing of vancomycin for 
efficacy and the narrowest margin for error with nephrotoxicity.  
1.3 AUC:MIC Ratio as the Pharmacokinetic/Pharmacodynamic Target 
As mentioned, the most recent consensus statement for vancomycin dosing and 
monitoring recommends a shift from trough-based dosing to AUC monitoring. 
Specifically, an area-under-the curve to minimum inhibitory concentration (AUC/MIC) 
ratio ≥ 400 is the recommended PK/PD efficacy target.23 A few caveats deserve mention 
on this topic prior to proceeding. First, this AUC/MIC recommendation primarily 
originates from in vitro and in vivo experiments,26-30 with some supporting observational 
clinical data,31,32 and failure to attain this AUC/MIC ratio may be associated with the 
emergence of MRSA resistance to vancomycin.33 Second, this AUC/MIC typically refers 






testing methods are highly variable, both among themselves and the reference BMD.34 
Furthermore, given that the BMD MIC90 is reportedly ≤ 1 mg/L in most institutions,35 
consensus guidelines recommend assuming an MIC of 1 mg/L unless otherwise known to 
be higher.23 This simplifies the vancomycin dosing target in practice to a 
pharmacokinetic target, rather than a PK/PD target. Third, although a change from 
trough-based dosing to AUC-based dosing has been associated with reduced 
nephrotoxicity,36 the upper limit of vancomycin AUC remains debated from the 
standpoint of nephrotoxicity risk. A number of studies, including a meta-analysis, have 
found AUC values slightly above 600 mg⸱hr/L as a critical threshold for additional 
nephrotoxicity risk.37 Accordingly, the recommended pharmacokinetic target for clinical 
use of vancomycin is 400-600 mg⸱hr/L.23 
1.4 Specific Aims 
Against this backdrop of evolving evidence of vancomycin use, my dissertation 
work is aimed at studying three techniques to optimize the efficacy and safety of 
vancomycin dosing in critically ill patients: loading doses, first-dose pharmacokinetic 
evaluation, and continuous infusions.  
1.4.1 Aim 1: To establish current dosing and monitoring practices regarding vancomycin 
use in critically ill patients. This will be accomplished via an online survey of practicing 
critical care pharmacists in adult critical care and sponsored by the pharmacy section of a 
multidisciplinary critical care organization. We will aim to establish critical care 
pharmacist self-reported compliance with the 2009 vancomycin guidelines as well as 
other nuances of vancomycin dosing and monitoring,38 with particular survey items 






pharmacokinetic evaluation, and continuous infusions, among others. We will also survey 
clinical practitioners on a group of hypothesized best practices for vancomycin dosing in 
critically ill patients that, while considered important by the research team, may not have 
had sufficient space in vancomycin consensus documents to comment on. This 
introductory study will serve to assess the clinical landscape of vancomycin dosing and 
monitoring in critically ill patients in current times. Based on a survey of infectious 
disease pharmacists from nearly 10 years ago,39 we anticipate non-universal adoption of 
loading doses of vancomycin. This prior survey39 identified a critical need to uncover 
clinician rationale for non-compliance with guideline recommendations, which we plan 
to address by not only asking about a variety of clinical scenarios for loading doses but 
also by asking pharmacists why they may not always use such an option. Commonly 
noted clinician hesitations will be considered in our clinical design of aim 2 assessing 
loading doses. Given the timing of the survey administration, we anticipate that few 
institutions are early adopters of AUC-guided dosing and that few pharmacists report 
using first-dose pharmacokinetic evaluation. Given the 2009 vancomycin guideline’s 
recommendation that “continuous infusions are unlikely to substantially improve patient 
outcome when compared with intermittent dosing”38 we also anticipate finding that few 
pharmacists are using continuous infusions of vancomycin, which we anticipate serving 
as important baseline preliminary data, and establishing the need for change efforts, 
should we identify continuous infusions of vancomycin reduce AKI compared to 
intermittent infusion.  
1.4.2 Aim 2: To assess the clinical benefit of a vancomycin loading dose in critically ill 






with the first dose, and given the increased Vd in critically ill patients, it is highly likely 
that critically ill patients require loading doses to produce sufficient serum concentrations 
to meet identified AUC/MIC goals. The 2020 vancomycin guidelines offer that a loading 
dose of 20-35 mg/kg actual body weight (up to 3,000mg) can be administered to critically 
ill patients with suspected or confirmed MRSA infection in order to more rapidly attain 
target serum concentrations; however, this recommendation is only supported by 
moderate evidence (BII; B- moderate evidence to support a recommendation for or 
against use, II- evidence from 1 or more well-designed clinical trials, without 
randomization; from cohort or case-controlled analytic studies (preferably from more 
than 1 center); from multiple time-series; or from dramatic results from uncontrolled 
experiments).23 Producing clinical evidence of benefit is challenging in any condition, but 
if there is a patient population of MRSA infections that would benefit from a loading 
dose, critically ill patients would appear to be highly likely as they are most at risk of 
poor outcomes from infection. In 2015, myself and another collaborator wrote a grant 
proposal to the Critical Care Pharmacotherapy Trials Network for a randomized, 
controlled trial of loading doses on pharmacokinetic target attainment and AKI, but valid 
concerns were noted in the review process of the extremely narrow time window allotted 
for informed consent in these situations of sepsis, where every hour delay in 
antimicrobial therapy within the first six hours is associated with a 7.6% reduction in 
survival.40 Additionally, the number of patients that would have to be enrolled to accrue a 
sufficient number of patients with documented MRSA cultures, and thus any sufficiently 
powered study of efficacy, would make the sample size infeasible. As such, it became 






be a cohort study. If we want clinicians to use loading doses, and if part of the reason 
they tell us they are not (which will be assessed in Aim 1) is due to lack of clinical 
efficacy data, then it is imperative to provide this evidence.  
1.4.3 Aim 3: To compare an approach of first-dose pharmacokinetic evaluation with 
empiric dosing of vancomycin on AUC target attainment at steady state in critically ill 
patients. Even though we now have clear guidance on the AUC goal of 400-600 mg⸱hr/L, 
it was clear to myself and practicing colleagues in the critical care units that our empiric 
approach to dosing vancomycin was often insufficient. Whenever vancomycin 
concentrations were assessed at steady state, we commonly found trough or AUC values 
outside of our target range. While nomograms of varying accuracy for vancomycin have 
existed for years, what could represent more of a personalized approach to dosing than 
assessing serum concentrations after a single dose and using a patient’s own 
pharmacokinetic response to develop more precise future dosing regimens? This 
approach of first-dose pharmacokinetic evaluation, indeed, has been studied for 
aminoglycosides41 and incorporated into clinical practice in certain scenarios. In revising 
our institution’s vancomycin dosing guidance, use of first-dose pharmacokinetic 
evaluation was added as an approved option for pharmacists dosing vancomycin, and 
particularly adopted in the medical ICU. The first-dose pharmacokinetic evaluation 
concept has previously been evaluated to a limited extent in adult and pediatric 
populations with mixed results.42,43 As they relate to vancomycin, prior studies evaluated 
target attainment as trough rather than the currently recommended AUC. Accordingly, no 
data exist on whether first-dose pharmacokinetic evaluation of vancomycin improves 






of AUC-guided vancomycin dosing, unique pharmacy practice model, and history of a 
robust therapeutic drug monitoring program, we are primed to study this issue assessing 
utility of first-dose pharmacokinetic evaluation, particularly in a targeted population of 
critically ill patients with wide variability in pharmacokinetic alterations. Following study 
of loading doses and first-dose pharmacokinetic evaluation, we will turn attention to the 
method of administration and focus on infusion strategy as a mechanism for precision 
dosing and maximizing safety.  
1.4.4 Aim 4: To perform a systematic review and meta-analysis on the risk of AKI in 
critically ill adults with continuous versus intermittent infusion of vancomycin. As noted 
earlier, AUC values routinely above 600 mg⸱hr/L have been associated with 
nephrotoxicity.37 Given their correlation, it is no surprise that vancomycin trough and 
peak concentrations have similarly been associated with nephrotoxicity to some 
extent.44,45 Data from animal models suggest that AUC or Cmax, but not trough, drive the 
nephrotoxicity of vancomycin as assessed by urinary kidney biomarkers of injury kidney 
injury molecule-1 (KIM-1) and osteopontin.6 Furthermore, in the same animal model, the 
previous investigators also showed that equivalent vancomycin doses given less 
frequently (once or twice daily administration, thus higher peak levels of the drug, 
compared to three or four times daily), showed higher levels of urinary KIM-1.46  
Vancomycin’s nephrotoxicity has long been known, but the precise mechanisms 
of toxicity remain debated.25 One proposed mechanism of toxicity includes disruption of 
mitochondrial function and production of reactive oxygen species, particularly in the 
proximal tubule cells of the kidney.47 Supporting this hypothesis, multiple antioxidants 






Secondly, vancomycin is filtered at the glomerulus and is both secreted and reabsorbed 
by the proximal tubule cells.49,50 Drugs such as cilastatin have been shown to block the 
reuptake of vancomyin by megalin, a major endocytic receptor on proximal tubule cells, 
and subsequently reduce the nephrotoxicity from vancomycin in pre-clinical models.51 
Third, a small series of biopsies from patients with confirmed vancomycin-associated 
nephrotoxicity (and with elevated vancomycin troughs) revealed obstructive tubular casts 
formed from non-crystal vancomycin aggregates in complex with uromodulin via an 
unknown mechanism.52 Given these findings associated with vancomycin nephrotoxicity, 
hypothesized mechanisms for reduced kidney injury with continuous infusions compared 
to intermittent infusions may be related to the availability of drug for uptake into the 
proximal tubule. By avoiding the high peak concentrations, either accessible to the 
proximal tubule by the basolateral membrane or via reabsorption from the apical 
membrane from the tubular lumen of the proximal tubule cell, this may keep the proximal 
tubule cell’s exposure to vancomycin below some critical threshold that initiates a series 
of events that alters mitochondrial function and cell proliferative response.53 
Complementary or alternatively, these higher peak concentrations may contribute to a 
saturation point that influences the cast nephropathy observed from human biopsy 
studies,52 although less is known about this mechanism of toxicity.  
Two smaller randomized controlled trials have previously studied continuous vs. 
intermittent infusions, however, a number of factors have changed since these studies, 
including vancomycin dosing targets (AUC vs. trough) as well as definitions for kidney 
injury with classifications over the years focusing on more sensitive definitions rather 






been published comparing the two infusion strategies, however, meta-analyses have 
either not focused on critically ill patients in particular56 or have applied meta-analytic 
techniques that pooled unadjusted data from studies rather than considering the adjusted 
estimates from individual studies.57 Given the smaller sample sizes of the pre-existing 
studies, a meta-analysis in this scenario can not only increase the overall sample size of 
patients considered, but also produces an informed prior estimate in terms of the effect 
size for planning of future comparative trials. Building from the meta-analysis, the final 
piece of the dissertation will focus on building a population pharmacokinetic model of 
continuous infusion vancomycin in critically ill patients.  
1.4.5. Aim 5: Build a population pharmacokinetic model of continuous infusion 
vancomycin in critically ill adults. In preparing for future work comparing continuous 
versus intermittent infusions of vancomycin, it will be critical to ensure that dosing 
regimens are equally precise in both arms. While the focus of algorithms, nomograms, 
and Bayesian software programs has been on intermittent infusions, much less focus has 
been given to building models of continuous infusion vancomycin, presumably due to the 
low frequency of use with which we anticipate observing in Aim 1. It is unknown if 
vancomycin administered continuously differs in its pharmacokinetic behavior compared 
to intermittent infusion. While a systematic review and meta-analysis revealed that 
continuous infusions of vancomycin had greater pharmacokinetic target attainment and 
lower variability compared to intermittent infusion,58 even with continuous infusions the 
pharmacokinetic target attainment rates were as low as 47-57% in some studies of 
critically ill patients.54,59 As with first-dose pharmacokinetic evaluation, we incorporated 






institutional vancomycin guidelines, again used primarily in the medical ICU. A 
prospective observational study of 50 patients will be planned based on guidance for 
number of subjects in population pharmacokinetic studies with sparse sampling,60,61 and a 
population pharmacokinetic model built from these data. Monte-Carlo simulations will be 
performed with the hope of developing simplified dosing nomograms depending on the 
findings from our population model.  
These five aims will allow for assessment of three different strategies for the 
difficult, but necessary task of precision dosing of vancomycin in critically ill patients. 
These series of studies are advantageous in that not only are they immediately applicable 
to direct clinical practice, but they will also serve as preliminary data for future study of 
optimizing vancomycin delivery to critically ill patients, in particular, further 
comparative effectiveness and urinary biomarker research between continuous and 
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From 2009-2020, guidelines for vancomycin dosing were available through a 
joint effort from the American Society of Health-System Pharmacists (ASHP), the 
Infectious Diseases Society of America (IDSA), and the Society of Infectious Diseases 
Pharmacists (SIDP).38 Despite availability of these guidelines and over 50 years of 
clinical experience, much remains unknown regarding the optimal use of vancomycin in 
clinical practice.62 A 2013 survey of infectious diseases pharmacists revealed discordance 
between vancomycin practices and guideline recommendations, particularly regarding a 
reluctance to use loading doses in seriously ill patients, to use actual body weight for dose 
calculation in obesity, and to systematically monitor for complications such as 
nephrotoxicity.39 
The compliance of pharmacists and physicians with guideline recommendations 
for vancomycin dosing and monitoring is important from an overall antimicrobial 
stewardship perspective, but is of particular importance in the critical care setting for 
several reasons. The complexities of the intensive care unit (ICU) patient population 
introduce additional challenges to a complex drug. The acuity of the patient population 
demands adequate pharmacokinetic-pharmacodynamic target attainment for serious, life-
threatening infections while minimizing the risk of nephrotoxicity for patients already at 
risk of acute kidney injury and often simultaneously prescribed multiple other 
nephrotoxins. Critically ill patients’ clearance of vancomycin could vary, from significant 
decreases in acute kidney injury to clinically significant increases in the setting of 
augmented renal clearance. Adjustments for other medical therapies, such as continuous 






circumstances that may not be addressed by guidelines. Other ‘best practice’ items 
related to vancomycin dosing in the critically ill are likely variable across ICU 
pharmacists due to unique aspects of this patient population.  
If any discordant areas of practice deviate in a substantial way from guideline 
recommendations, understanding factors driving critical care pharmacists’ decisions to do 
so are important to elucidate and represent cornerstones of implementation science 
efforts. The purpose of this survey was to determine if this variability exists in an effort 
to potentially inform future guideline recommendations and to reduce variability in 
evidence-based practices. We sought to build on a prior survey of vancomycin use39 in 
the following ways: 1. To perform a more recent survey of practice patterns given the 
continuously updated literature on vancomycin since 2013, 2. To study under which 
clinical scenarios ICU pharmacists may not adhere to guideline recommendations and 
ascertain why, 3.) To characterize practice patterns regarding ICU-centric dosing 
challenges that may not be addressed in consensus guidelines, and 4. To explore 
respondent characteristics associated with compliance to guideline recommendations or 
early adoption of certain vancomycin dosing practices.     
2.2 Materials and Methods 
2.2.1 Survey Design 
A survey was developed by a pharmacist working group of the Society of Critical 
Care Medicine (SCCM) Clinical Pharmacy and Pharmacology (CPP) Research and 
Scholarship Committee in early 2017. This survey was approved by the University of 






Survey questions were developed by the working group using the 2009 
ASHP/IDSA/SIDP guidelines as a template.38 Once guideline recommendations were 
addressed in the survey, the additional survey questions were created to capture 
additional areas of what the authors considered “best practice” or areas where substantial 
variability in practice was hypothesized to exist; for example, whether pharmacists were 
alerted to initiation or discontinuation of renal replacement therapies to adjust dosing 
accordingly. The survey was a 24-item questionnaire, with six general demographic 
questions, eight vancomycin-related demographic questions regarding the practice site, 
and 10 questions related to individual clinician’s vancomycin dosing practices 
(Appendix 1). 
A modified Likert scale was used: rarely (<10% of the time); sometimes (10-50% 
of the time); often (51-90% of the time); and routinely (>90% of the time) was used for 
questions of which a frequency of a particular action was inquired (e.g. how often a 
clinician would recommend an intervention). A pilot survey was performed by 5 non-
critical care pharmacists to establish face and content validity of the survey instrument. 
Six critical care pharmacists not involved on the study team took the survey to estimate 
time required for completion and provide any additional feedback or areas for 
clarification. Verbal and written feedback from all pilot tests were incorporated into the 
final survey by the research team. The survey required approximately 10-15 minutes for 
completion. 
2.2.2 Cross-Sectional Survey 
Invitations to complete the survey were sent over e-mail twice, two weeks apart 






REDCap electronic data capture tools hosted at the University of Kentucky.63 Invitations 
were sent out electronically via SCCM staff to all SCCM members of the CPP section, 
which includes pharmacist and non-pharmacist members. Pharmacist members of CPP 
practicing in adult critical care settings were specifically invited to take the survey and 
represent the target population of interest. Non-pharmacist members, or pharmacists 
practicing in a pediatric critical care setting, were asked not to respond to the survey.  
2.2.3 Statistical Analysis 
Data were analyzed with Stata (StataCorp. 2015. Stata Statistical Software: 
Release 14. College Station, TX: StataCorp LP). Categorical data from the survey are 
presented as proportions. Exploratory logistic regression analyses were undertaken to 
evaluate factors associated with the following: selection of often or routinely (e.g. >50% 
of the time) for loading doses for all six clinical scenarios examined, use of area-under-
the-curve (AUC) as pharmacokinetic target parameter, and self-reported comfort with 
AUC calculations (i.e. somewhat or extremely comfortable). Candidate predictor 
variables identified a priori by the study team thought to influence vancomycin dosing 
practices included: region, practitioner years of experience, hospital type, hospital size, 
and ICU type. Due to complete separation of variables in some of the regression models, 
a penalized maximum likelihood regression model was used with the firthlogit package in 
Stata.64-66 Output from regression models are presented as odds ratios (OR) with 95% 








2.3.1 Survey Response Rate 
The survey was delivered to 2,305 SCCM CPP members (includes pharmacists 
and non-pharmacists) via e-mail using the SCCM CPP section distribution list. 
Approximately 1,500 of these members are pharmacists within the CPP section per the 
SCCM demographic database. Based on internal demographic data from the section 
indicating that approximately 100 pharmacists practiced in pediatric critical care, we 
estimate that 1,400 of these pharmacists practiced in an adult ICU setting and would be 
eligible for the survey. We received 364 responses, for an estimated response rate of 
26%.  
2.3.2 Respondent Demographics  
 Respondent demographics are presented in Table 2.1. Approximately half (48%) 
of respondents were from urban academic medical centers. The two most frequent 
responses for institutional bed size were 250-499 beds and 500-750 beds. The large 
majority of respondents (>97%) were from the United States with relatively similar 
representation from all major geographic areas. A majority of pharmacists participating in 
the survey were clinical practitioners < 5 years (33%) or 5-10 years (29%) removed from 
their terminal training. These pharmacists most frequently practiced in a medical (30%) 
or mixed medical/surgical (32%) ICU. Over 90% of pharmacist respondents reported that 






2.3.3 Vancomycin-Related Practices in Respondent Institutions 
 Practice site characteristics regarding vancomycin are presented in Table 2.2. The 
most common responses regarding what percentage of Staphylococcus aureus isolates 
were methicillin-resistant Staphylococcus aureus (MRSA) were either 20-39% (23% of 
respondents) or 40-59% (34% of respondents). Vancomycin was routinely reported as 
empiric therapy in hospital-acquired infections by 67% of respondents. Fifty-five percent 
of respondents estimated the average duration of vancomycin use prior to de-escalation 
when MRSA is not cultured as 48-72 hours. A large majority of respondents (85%) 
reported that their institution reports the vancomycin minimum inhibitory concentrations 
for MRSA in the medical record.  
Approximately one-third of respondents (31%) reported their institution had no 
formal pharmacy consult order (or pharmacy to dose protocol) to dose vancomycin. 
Another 31% of respondents reported that pharmacists may deviate from the protocol as 
written, which they sometimes do (10-50% of the time). The majority of pharmacists had 
a protocol or other mechanism in place to order vancomycin serum concentrations (83%), 
laboratory monitoring (e.g., such as a basic metabolic panel) (72%), or dose adjust 
according to vancomycin serum concentration or renal function (78%); 18% of 
respondents reported no formal mechanism for placing these orders, requiring they be 
placed under a provider’s name pursuant to a verbal or written order.  
Twenty percent of respondents reported a protocol for vancomycin dosing in the 
setting of CRRT with a mechanism to alert the pharmacist that CRRT is being initiated or 






CRRT initiation or discontinuation. Most respondents (60%) did not use sustained low 
efficiency dialysis (SLED) at their practice site.  
When asked which vancomycin monitoring and quality assurance programs were 
offered at their institutions, respondents indicated low rates of participation with regard to 
quality assurance for percentage of vancomycin dosing within a goal parameter (26%), 
clinical decision support to identify acute changes in serum creatinine or urine output 
(25%), and standardized definition of vancomycin-associated nephrotoxicity (7%). 
2.3.4 Respondent Vancomycin Dosing Practices 
 Complete results are displayed in Table 2.3. With respect to scenario-based 
questions regarding use of vancomycin loading doses, responses were mixed across 
scenarios. The percentage of pharmacists reporting either routinely or often (51-90% of 
the time) using a loading dose for the surveyed conditions were as follows: 
meningitis/CNS infection (84%), septic shock (79%), infective endocarditis (75%), 
pneumonia in a mechanically ventilated patient (69%), sepsis without shock (61%), and 
pneumonia in a non-mechanically ventilated patient (54%). When respondents were 
asked why they did not administer a loading dose at times for a critically ill patient, the 
most common response was that their assessment of the patient did not meet the 
definition of severely ill (40%), followed by lack of clinical outcome data supporting the 
loading dose strategy (23%) and nephrotoxicity concerns (20%). Written comments by 
survey respondents suggested other possible reasons, including physician concerns for 






versus using doses readily available in the patient care area from automated dispensing 
cabinets.   
 Over 90% of respondents reported using actual body weight for loading doses and 
maintenance doses in normal or underweight patients. For overweight or obese patients, 
56% of respondents reported using actual body weight (41% used adjusted body weight) 
for a loading dose and 45% of respondents reported using actual body weight (51% used 
adjusted body weight) for maintenance dosing. The most commonly reported dose cap 
for a loading dose was 2,000 mg (45%) followed by 2,500 mg (28%), while 2,000 mg 
was the most commonly reported dose cap for maintenance dosing with the majority of 
respondents (75%).  
 The majority of respondents reported rarely assessing post-loading dose 
concentrations, two level kinetics following the first dose, and peak levels. The vast 
majority (87%) of respondents reported using trough values while 13% reported using 
trough and AUC. When using trough values, 24% of respondents report that doses are 
held routinely pending evaluation of the level, while 64% report doses are held pending 
evaluation only in the setting of suspected acute kidney injury.  
 Pharmacists most commonly (92%) reported administering vancomycin via 
intermittent infusion with the majority of pharmacists rarely using continuous infusion. 
Pharmacist perception of their comfort level with AUC calculations was variable with 
intermittent infusion. The majority of respondents (62%) report being not at all 






 In exploratory regression models, respondents from larger hospitals were overall 
less likely than smaller hospitals to report consistently using loading doses often or 
routinely in all six scenarios presented: 250-499 beds (OR 0.4, 95% CI 0.2-0.9), 500-750 
beds (OR 0.4, 95% CI 0.2-0.9), and > 750 beds (OR 0.4, 95% CI 0.2-0.8) [reference 
hospitals with < 250 beds]. Europe (OR 22.8, 95% CI 2.3-228.7) and Western US regions 
(OR 3.6, 95% CI 1.5-8.6) were more likely to report using AUC as a target 
pharmacokinetic parameter for vancomycin use. No predictors were identified for 
reported comfort with AUC calculations.     
2.4 Discussion 
 Compliance with clinical practice guidelines is influenced by many factors, 
notably the quality of the guidelines themselves, users of the guidelines, and 
implementation context.67 Critical care pharmacists were overall compliant with many of 
the 2009 guideline recommendations assessed except for a few particular areas. 
Specifically, we observed inconsistent use of a loading dose, dosing weight in obese 
patients, and quality improvement efforts related to systematically monitoring 
vancomycin-associated nephrotoxicity. 
A survey of infectious disease pharmacist self-reported adherence to the 2009 
guidelines was previously published in 2013.39 Key variations in infectious disease 
pharmacist reported practices from 2009 guideline recommendations involved the 
recommendations around loading doses in seriously ill patients (only 42% reported 
always), use of actual body weight to dose obese patients (40% reported sometimes; 52% 






to routinely identify and report vancomycin-associated nephrotoxicity (34% reported 
never; 35% reported sometimes).39 The authors of this study noted it imperative to 
discern reasons for noncompliance to the loading dose recommendation, particularly in 
severely ill patients who may benefit and have altered pharmacokinetics.39 Our survey 
builds on prior work with a larger and more diverse study sample and is unique by 
focusing on adult critical care pharmacists, includes survey items regarding sources of 
practice variation related to vancomycin in critically ill patients, and investigates reasons 
for pharmacists not adhering to certain 2009 guideline recommendations.   
 Our survey also identified variation in compliance with loading dose 
recommendations; however, some pharmacists report practicing differently in specific 
scenarios. In particular, their assessment of severity of illness appears to be a large factor 
in administering a loading dose. Although some respondents may consider an ICU patient 
“severely ill” as the 2009 guidelines term it, this classification can be subjective.38 Lack 
of clinical outcomes behind the 2009 recommendation for loading doses (IIIB 
recommendation) and concerns of nephrotoxicity in an already at-risk patient population 
are also commonly reported reasons for selectively administering loading doses.38 
Concerns of nephrotoxicity with loading doses by physician colleagues were also noted 
in the written responses from pharmacist respondents in this survey and identified as 
potential barriers to routinely using loading doses.  
There were similar discrepancies between using actual body weight for dosing in 
obese patients between the two surveys, with a number of pharmacists in the current 
survey reporting use of an adjusted body weight.39 The pharmacokinetics of vancomycin 






vancomycin and the increase in adipose tissue associated with obesity, its volume of 
distribution is somewhat increased in obese patients. In addition, various dosing weights, 
including ideal body weight, total body weight, and adjusted body weight, have been 
evaluated in estimating clearance of vancomycin with conflicting results.69 Given the 
complexity of critically ill, obese patients and a lack of strong evidence for how to 
optimally dose vancomycin in these patients, it is not surprising that our survey revealed 
such practice variation.  
 In both our survey and that of Davis et al,39 there do seem to be opportunities 
related to standardized definitions of vancomycin-associated nephrotoxicity and quality 
improvement programs to track and monitor this complication. The possibility exists that 
this is done within the context of antimicrobial stewardship programs and surveyed ICU 
pharmacists may not be aware, but this was reported as similarly low in the survey of 
infectious diseases pharmacists.39 Additionally, an opportunity may exist for more 
institutions to implement CRRT alert triggers for pharmacists to increase or decrease 
doses, as appropriate.  
 The majority of critical care pharmacists surveyed rarely employed continuous 
infusion dosing of vancomycin. Interestingly, recent evidence suggests that continuous 
infusions may be less nephrotoxic than intermittent infusions, particularly in critically ill 
patients.56,70,71 Of paradoxical interest is that pharmacists were reportedly far less 
comfortable with AUC calculations for continuous infusions than with intermittent 
infusions, given the AUC calculations for continuous infusion are much simpler than for 
intermittent dosing. The varying comfort level with AUC calculations in this survey 






guided dosing in ICU patients on a larger scale, as is recommended by the revised 
vancomycin consensus guidelines recently published in May of 2020.23   
 Our exploratory analysis found that respondents from larger hospitals were 
generally less likely to report consistent use of loading doses compared to respondents 
from hospitals with < 250 beds. While the exact reasoning for this is unknown, it could 
be due to a relatively smaller number of respondents from hospitals with < 250 beds 
(15.1% of respondents) or perhaps improved compliance with protocols and guideline 
recommendations in smaller hospitals from this survey. Additionally, our analysis 
suggests geographic variation in early adoption of AUC to guide vancomycin dosing, 
with greater adoption in Western United States and Europe at the time our survey was 
administered. Pharmacist education is clearly required for AUC dosing and monitoring 
given the reported comfort rates. Although the pharmacokinetic assumptions are fewer 
and calculations easier with continuous infusion, this may simply represent the 
unfamiliarity of critical care pharmacists surveyed with employing continuous infusions 
due to the low frequency of use identified.  
Our study has important limitations to acknowledge. Only SCCM CPP members 
participated in the study; thus, reported behaviors from non-survey responders and non-
SCCM CPP members may be different. This survey only inquired about self-reported 
actions regarding vancomycin and may not reflect actual actions from clinicians in their 
practice. Multiple respondents may have responded from the same institution, thus 
biasing some reported metrics. Our response rate of 26% limited the number of 
respondents that we were able to collect data from, however, our study is more than twice 






identified as using AUC more than others in this survey, there were few respondents from 
Europe, which may only represent a few institutions and not be representative of 
European practice. Finally, our survey was disseminated in the spring of 2017, and we 
suspect additional centers have transitioned to AUC monitoring at this time given a signal 
of increased safety in terms of kidney injury  as well as anticipated (and actual) 
endorsement of AUC guided dosing in recently released revised consensus vancomycin 
guidelines.23,36,72 Although these revised guidelines have been published since our survey, 
aside from recommending a change from trough-based dosing to AUC and no longer 
directly recommending actual body weight in maintenance dosing for obesity, many of 
the recommendations as they relate to our survey remain similar between the 2009 and 
2020 guidelines.23,38 Table 2.4 compares relevant dosing considerations from our survey 
between the 2009 and 2020 guidelines.23,38 Our data may serve as a benchmark in 
evaluating uptake of consensus guideline recommendations, particularly against the 
backdrop of showing a relatively low ‘early-adopter’ rate for AUC-guided dosing. In the 
context of newly revised consensus guidelines, we also show continued room for 
improvement with the guideline recommendation for loading doses, and demonstrate that 
a small percentage of surveyed pharmacists are employing continuous infusion. Finally, 
our survey also establishes the prevalence of important dosing concepts that may not be 
presented as formal guideline recommendations yet may reflect best practices in dosing 
vancomycin in critically ill patients, including electronic alerts for CRRT initiation or 







Critical care pharmacists’ reported practices regarding vancomycin are largely consistent 
with the 2009 vancomycin guideline recommendations. Important areas of variation 
include use of loading doses, dosing weights in obese patients, and quality improvement 
efforts related to systematically monitoring vancomycin-associated nephrotoxicity. 
Further study in these particular areas may allow more definitive guideline 






Table 2.1 Respondent Demographics 
 Number (%) 
Practice Region 
 Midwestern United States 111/364 (30.5) 
 Southern United States 109/364 (30.0) 
 Western United States 74/364 (20.3) 
 Northeastern United States 60/364 (16.5) 
 Outside of United States 10/364 (2.7) 
Institutional Setting 
 Academic medical center/urban 174/364 (47.8) 
 Community hospital/teaching/urban 89/364 (24.5) 
 Community hospital/non-teaching/urban 44/364 (12.1) 
 Other (including government and rural hospitals) 57/364 (15.6) 
Institution Size 
 < 250 beds 55/364 (15.1) 
 250-499 beds 119/364 (32.7) 
 500-750 beds 99/364 (27.2) 
 > 750 beds 91/364 (25.0) 
Current Level of Training 
 Current PGY2 specialty pharmacy resident (any specialty)  35/364 (9.6) 
 Practitioner less than 5 years out from terminal training 121/364 (33.2) 
 Practitioner 5-10 years out from terminal training 104/364 (28.6) 
 Practitioner more than 10 years out from terminal training 99/364 (27.2) 
 Other 5/364 (1.4) 
Primary Location or Service 
 Cardiothoracic ICU 20/364 (5.5) 
 Emergency Department 20/364 (5.5) 
 Medical ICU 109/364 (29.9) 
 Mixed Medical/Surgical ICU 115/364 (31.6) 
 Surgical/Trauma ICU 49/364 (13.5) 
 Other 51/364 (14.0) 
Pharmacists Physically Round with the Primary or Intensivist Team ≥ 5 days/Week 














Table 2.2 Practice Site Characteristics and Vancomycin-Related Demographics  
 Number (%) 
Institutional Protocol Description and Pharmacist Adherence 
 Pharmacists must adhere to the protocol as written and may not deviate 8/364 (2.2) 
 Pharmacists may deviate from the protocol as written, but I rarelya do 36/364 (9.9) 
 Pharmacists may deviate from the protocol as written, which I sometimesb do 111/364 (30.5) 
 Pharmacists may deviate from the protocol as written, which I oftenc do 63/364 (17.3) 
 Pharmacists may deviate from the protocol as written, and I routinelyd do 34/364 (9.3) 
 No formal protocol exists in my primary practice 112/364 (30.8) 
Pharmacist Authorized to Order 
 Vancomycin levels 303/364 (83.2) 
 Laboratory tests for monitoring (e.g., basic metabolic panel) 262/364 (72.0) 
 Dose adjustments based on vancomycin levels or renal function changes 283/364 (77.8) 
Institutional Protocol for Vancomycin Dosing in Continuous Renal Replacement Therapy (CRRT) 
 Yes; but there is no mechanism to alert the pharmacist that CRRT is being 
initiated or discontinued 109/364 (29.9) 
 Yes; and there is a mechanism to alert the pharmacist that CRRT is being 
initiated or discontinued 71/364 (19.5) 
 No; and there is no mechanism to alert the pharmacist that CRRT is being 
initiated or discontinued 93/364 (25.6) 
 No; but there is a mechanism to alert the pharmacist that CRRT is being 
initiated or discontinued 51/364 (14.0) 
 Primary practice ICU does not utilize CRRT 40/364 (11.0) 
Institutional Vancomycin Monitoring and Quality Assurance Programs 
 Quality assurance for percentage of vancomycin dosing regimens within goal target 
parameters 96/364 (26.4) 
 Real-time clinical decision support to notify pharmacists of acute changes in serum 
creatinine or urine output 90/364 (24.7) 
 Standardized definition of vancomycin-associated nephrotoxicity 27/364 (7.4) 
 None of these 159 (43.7) 
Estimated Methicillin Resistant Staphylococcus aureus Isolates 
 20-39% 84/364 (23.1) 
 40-59% 122/364 (33.5) 
 60-80% 25/364 (6.9) 
 Other 32/364 (8.8) 
 Unknown/No specific antibiogram  101/364 (27.7) 
Estimated Frequency of Empiric Vancomycin Therapy for Suspected Hospital-Acquired 
Infections 
 Rarelya 6/364 (1.6) 
 Sometimesb 16/364 (4.4) 
 Oftenc 99/364 (27.2) 
 Routinelyd 243/364 (66.8) 
Estimated Average Duration of Vancomycin Use Prior to De-escalation when MRSA is Not 
Cultured 
 < 2 days (< 48 hours) 16/364 (4.4) 
 2-3 days (48-72 hours) 201/364 (55.2) 
 3-4 days (72-96 hours) 109/364 (30.0) 
 > 4 days (> 96 hours) 38/364 (10.4) 







Table 2.3 Vancomycin Dosing and Monitoring Strategies  
Frequency of Loading Dose Recommendation By Indication 
  Rarelya Sometimesb Oftenc Routinelyd 
 Infective endocarditis 52/364 (14.3) 40/364 (11.0) 70/364 (19.2) 202/364 (55.5) 
 Meningitis/CNS infection 33/364 (9.1) 27/364 (7.4) 54/364 (14.8) 250/364 (68.7) 
 Pneumonia in a MV 
patient 
51/363 (14.1) 60/363 (16.5) 75/363 (20.7) 177/363 (48.8) 
 Pneumonia in a non-MV 
patient 
94/363 (25.9) 74/363 (20.4) 71/363 (19.6) 124/363 (34.2) 
 Sepsis with shock 40/364 (11.0) 38/364 (10.4) 68/364 (18.7) 218/364 (59.9) 
 Sepsis without shock 67/363 (18.5) 74/363 (20.4) 82/363 (22.6) 140/363 (38.6) 
Pharmacist Reasoning When Choosing Not to Administer a Loading Dose 
 Lack of clinical outcome data supporting strategy 83/364 (22.8) 
 Nephrotoxicity concerns 73/364 (20.1) 
 Time required to infuse 13/364 (3.6) 
 The patient does not meet my definition of severely ill 146/364 (40.1) 
 Other 71/364 (19.5) 
Most Commonly Used Weight for Dosing Vancomycin 






 Loading dose for normal/underweight 
patients 353/361 (97.8) 5/361 (1.4) 3/361 (0.8) 
 Loading dose for overweight/obese 
patients 201/361 (55.7) 12/361 (3.3) 148/361 (41.0) 
 Maintenance dose for 
normal/underweight patients 341/361 (94.5) 9/361 (2.5) 11/361 (3.1) 
 Maintenance dose for overweight/obese 
patients 162/361 (44.9) 16/361 (4.4) 183/361 (50.7) 
Most Commonly Used Dose Cap 
  2000 mg per 
dose 
2500 mg per 
dose 
3000 mg per 
dose 




 Loading dose 164/362 
(45.3) 
102/362 




(75.4) 43/362 (11.9) 10/362 (2.8) 2/362 (0.6) 34/362 (9.4) 
Use of the Following Strategies to Assess Vancomycin Exposure and Calculate Further Dosing 
  Rarelya Sometimesb Oftenc Routinelyd 
 Collect a post-loading 
dose level 
322/361 (89.2) 29/361 (8.0) 3/361 (0.8) 7/361 (1.9) 
 Two-level kinetics after 
first dose 
277/361 (76.7) 63/361 (17.5) 14/361 (3.9) 7/361 (1.9) 
 Collect peak levels 325/361 (90.0) 21/361 (5.8) 6/361 (1.7) 9/361 (2.5) 
 Collect trough levels 9/362 (2.5) 18/362 (5.0) 32/362 (8.8) 303/362 (83.7) 
Frequency of Doses Held Pending Level Evaluation When Trough Levels are Collected 
 Doses are held routinely (>90% of the time) pending level evaluation 87/362 (24.0) 
 Doses are held pending level evaluation only if kidney injury is suspected or 
known 233/362 (64.4) 
 Doses are held rarely (< 10% of the time), even if kidney injury is suspected 








Table 2.3 (continued) 
Target Pharmacokinetic Dosing and Monitoring Parameter  
Trough 314/363 (86.5) 
AUC 2/363 (0.6) 
Trough and AUC 47/363 (12.9) 
Frequency of Vancomycin Dosing via Method of Administration 
 Rarelya Sometimesb Oftenc Routinelyd 
Intermittent 
infusion 
10/364 (2.8) 11/364 (3.0) 8/364 (2.2) 335/364 (92.0) 
Continuous 
infusion 
342/363 (94.2) 16/363 (4.4) 3/363 (0.8) 2/363 (0.6) 
Comfort Level Assessing Vancomycin Levels to Calculate AUC 










134/363 (36.9) 54/363 (14.9) 100/363 (27.6) 75/363 (20.7) 
Continuous 
infusion 
223/362 (61.6) 59/362 (16.3) 49/362 (13.5) 31/362 (8.6) 
a = < 10% of the time; b = 10-50% of the time; c = 51-90% of the time; d = > 90% of the time; AUC= area-



















Table 2.4 Comparisons Between 2009 and 2020 Vancomycin Consensus Guidelines 
Relevant to Survey of Dosing Practices 
Dosing Consideration  2009 Vancomycin 
Guidelines38 
2020 Revised Consensus 
Guidelines23 
Monitoring Parameters “Trough serum vancomycin 
concentrations are the most 
accurate and practical 




with a target of 15-20 mg/L, 
is no longer recommended 
based on efficacy and 
nephrotoxicity data in 
patients with serious 
infections due to MRSA” 
(A-II) 
 
“In patients with suspected 
or definitive serious MRSA 
infections, an individualized 
target of the AUC/MIC ratio 
of 400 to 600 (assuming a 
vancomycin MIC of 1 mg/L) 
should be advocated to 
achieve clinical efficacy 
while improving patient 
safety.” (A-II) 
Loading Dose and 
Weight 
“In seriously ill patients, a 
loading dose of 25-30 mg/kg 
(based on actual body 
weight) can be used to 
facilitate rapid attainment of 
target trough serum 
vancomycin concentration.” 
(IIIB)  
“In order to achieve rapid 
attainment of targeted 
concentrations in critically 
ill patients with suspected or 
documented serious MRSA 
infections, a loading dose of 
20 to 35 mg/kg can be 
considered for intermittent-
infusion administration of 
vancomycin.” (B-II) 
 
“Loading doses should be 
based on actual body weight 
and not exceed 3,000 mg. 
More intensive and early 
therapeutic drug monitoring 
should also be performed in 













should be calculated on 
actual body weight. For 
obese patients, initial dosing 
can be based on actual body 
weight and then adjusted 
based on serum vancomycin 
concentrations to achieve 
therapeutic levels.” (IIA)  
“Initial maintenance doses of 
vancomycin can be 
computed using a population 
pharmacokinetic estimate of 
vancomycin clearance and 
the target AUC in obese 
patients. Empiric 
maintenance doses for most 
obese patients usually do not 
exceed 4,500 mg/day, 
depending on their renal 
function.” (B-II) 
Continuous Infusion “Continuous infusion 
regimens are unlikely to 
substantially improve patient 
outcome when compared 
with intermittent dosing.” 
(IIA) 
“The pharmacokinetics of 
continuous infusion suggest 
that such regimens may be a 
reasonable alternative to 
conventional intermittent-
infusion dosing when the 



































This work has previously been published and is distributed under the terms of the 
Creative Commons Attribution-NonCommercial 4.0 License: 
 
Flannery AH, Wallace KW, Rhudy CN, Olmsted AS, Minrath RC, Pope SM, 
Cook AM, Burgess DS, Morris PE. Efficacy and Safety of Vancomycin Loading Doses 
in Critically Ill Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) 








Methicillin-resistant Staphylococcus aureus (MRSA) is a significant pathogen in 
critically ill patients.  In a nationwide surveillance study of United States hospitals, 
Staphylococcus aureus was responsible for 20% of nosocomial bloodstream infections, 
with an alarming increase in MRSA isolates more than doubling from 22% to 57% over 
the period from 1995-2001.8 In critically ill patients, MRSA bacteremia is associated with 
a 22.1% higher attributable mortality rate compared to methicillin-sensitive 
Staphylococcus aureus (MSSA).9 S. aureus is isolated in approximately one out of every 
five cases of ventilator-associated pneumonia, with approximately 56% MRSA isolates.10 
Recent data suggest that inadequate attainment of a therapeutic vancomycin area-
under-the-curve (AUC) to minimum inhibitory concentration (MIC) ratio on days 1 and 2 
of therapy in MRSA bacteremia is associated with treatment failure.73 Critically ill 
patients commonly receive significant fluid resuscitation and experience fluid shifts from 
the intravascular to the extravascular compartment, which increases the volume of 
distribution (Vd) for hydrophilic drugs such as vancomycin.24,74 Accordingly, recently 
updated consensus guidelines on vancomycin state that a loading dose of 20-35 mg/kg 
actual body weight (not to exceed 3,000 mg) can be considered for critically ill patients 
with suspected or confirmed MRSA infection in order to ensure rapid attainment of 
appropriate serum concentrations.23 However, this recommendation is limited by 
moderate strength of recommendation (B) and quality of evidence (II), and is primarily 
based on pharmacokinetic outcomes rather than a documented clinical benefit.23 
In a recent survey of practitioners regarding vancomycin dosing in critically ill 






a variety of clinical scenarios was highly variable, with respondents often citing the lack 
of evidence for the clinical decision to forego a loading dose, followed by concerns of 
nephrotoxicity.75 Given that critically ill patients are particularly vulnerable to poor 
outcomes from MRSA infection and exhibit altered pharmacokinetics of vancomycin that 
may place them at risk of missing identified pharmacokinetic-pharmacodynamic targets, 
they are logically the population to gain the most benefit from loading doses of 
vancomycin. As such, we sought to determine if critically ill patients with MRSA 
infection demonstrated improved clinical outcomes when receiving vancomycin loading 
doses (versus not) in order to provide needed clinical data to augment the 
pharmacokinetic outcomes previously assessed in studies of vancomycin loading doses.  
3.2 Material and Methods 
3.2.1 Study Design 
This was a single center, retrospective cohort study of critically ill patients 
admitted to any intensive care unit (ICU) from January 2008 to October 2016 within a 
865-bed tertiary academic medical center that serves as a referral center for the state and 
surrounding regions. Patients were included in the study if they had a positive respiratory 
or blood culture for MRSA and had vancomycin initiated for MRSA during or up to 48 
hours before an ICU admission. Exclusion criteria were as follows: weight ≥ 125 kg, any 
MRSA culture other than from blood or respiratory source, <1,000 colony forming 
units/ml or 1-2% MRSA on respiratory cultures, loading dose information missing (i.e. 
from outside hospital), or if vancomycin was started > 48 hours prior to the ICU 
admission. We elected to study pneumonia and bacteremia given the frequency of these 






infections (i.e. skin and soft tissue) in an attempt to prognostically enrich the study for 
patients that might clinically benefit from a loading dose of vancomycin.76 A weight of ≥ 
125 kg was excluded so as not to confound the assessment of loading doses on a 
milligram per kg of actual body weight basis. Patients were classified into two cohorts 
based on their initial vancomycin dose received: loading dose (≥ 20 mg/kg actual body 
weight) or no loading dose (<20 mg/kg actual body weight).  
The primary outcome was clinical failure, defined as a composite outcome with 
similar definitions as prior studies of MRSA infection,77,78 which included: death within 
30 days of first MRSA culture, blood cultures positive ≥ 7 days, white blood cell (WBC) 
count >12 x103 /mm3 up to 5 days from vancomycin initiation, temperature >100.4°F up 
to 5 days from vancomycin initiation, or substitution (or addition) of another targeted 
anti-MRSA antibiotic such as daptomycin, linezolid, or ceftaroline. The primary outcome 
was adjudicated in the order of the outcomes stated above, thus while some patients may 
have had more than one definition of clinical failure, each patient was only classified 
with one of the definitions based on the sequential order assessed.  
Secondary outcomes included all-cause mortality in the ICU, time from 
vancomycin initiation to ICU discharge, acute kidney injury (AKI) within 5 days of 
vancomycin initiation as assessed by the serum creatinine component of the Kidney 
Disease Improving Global Outcomes (KDIGO) criteria,79 first vancomycin serum trough 
concentration value, and duration of vasopressor support, if applicable. Data were 
extracted from the electronic data warehouse and manual chart review was performed on 
all included patients to ensure integrity of the data. Data were collected on patients to 






investigators as being associated with receipt of a loading dose including severity of 
illness assessments such as Sequential Organ Failure Assessment score (SOFA)80 and Pitt 
bacteremia score (PBS),81,82 need for mechanical ventilation or vasopressor support at the 
time of vancomycin initiation, hospital service (classified into medical or surgical ICUs), 
history of kidney disease, and kidney function at the time of vancomycin initiation. 
Vancomycin MICs were determined per Clinical and Laboratory Standards Institute 
standards by broth microdilution via automated susceptibility testing methods with the 
Phoenix™ Automated Microbiology System (BD Diagnostics, Sparks, MD, USA) from 
1/2008 to 10/2013 and 4/2016 to 10/2016 and Etest (bioMérieux, Marcy l’Etoile, France) 
from 11/2013 to 3/2016.  Receipt of concurrent nephrotoxins within 5 days of receiving 
the loading dose was classified as the receipt of any of the following: angiotensin 
converting enzyme inhibitors, angiotensin receptor blockers, intravenous (IV) acyclovir, 
aminoglycosides, amphotericin B, colistin, foscarnet, non-steroidal anti-inflammatory 
drugs, polymyxin B, sulfamethoxazole/trimethoprim, IV tacrolimus, and 
piperacillin/tazobactam. The study was approved by the institutional review board at the 
University of Kentucky (#54961) with a waiver of informed consent given the study 
design.  
3.2.2 Statistical Analysis  
Based on prior studies of MRSA infections suggesting clinical failure rates as 
high as 41%,77,78 and assuming a higher percentage due to the requirement for critical 
illness in our study, we anticipated a baseline clinical failure of 60%. In order to detect a 






group (194 patients in total) to achieve 80% power with an α = 0.05 for the primary 
composite outcome.  
Descriptive statistics were used to summarize categorical variables as percentages 
and continuous variables as medians (interquartile range [IQR]). Independent samples 
were compared using the chi-square test or Wilcoxon rank-sum test as appropriate. Given 
the relatively high frequency of death anticipated from studying critically ill patients, we 
analyzed time to ICU discharge from vancomycin initiation with a competing-risks 
regression approach using the methods of Fine and Gray83 with death as a competing 
event and displayed graphically with a cumulative incidence function. Analysis of 
clinical failure by primary infection site (isolated bacteremia or pneumonia) between the 
loading dose and no loading dose groups was a pre-planned secondary analysis. 
Exploratory analyses of the primary outcome included the reconstruction of the loading 
dose variable in quartiles rather than a dichotomous variable, and evaluation of initial 
doses of ≥1,750 mg vs. <1,750 mg as hypothesized by other research groups to have 
benefit.77 We built a multivariable logistic regression model for the composite outcome 
of clinical failure using the following pre-specified variables with complete data present 
identified by the study team with the potential to influence either the receipt of a loading 
dose or outcome of clinical failure at the time the vancomycin loading dose was 
administered: vancomycin initial dose (as a continuous mg/kg variable), age, sex, MRSA 
culture site, chronic or end-stage renal disease, ICU service, day 1 maximum values for 
WBC, blood urea nitrogen, serum creatinine, and temperature, SOFA score, need for 
vasopressor support, or need for mechanical ventilation. The PBS was not included due 






factors were used to assess collinearity and ensure all variables were appropriate to retain 
in the model. Statistical analyses were performed in Stata (StataCorp. 2019. Stata 
Statistical Software: Release 16. College Station, TX: StataCorp LLC) and SAS (SAS 
Institute Inc., Cary, NC, USA). Statistical significance was set at p< 0.05.   
3.3 Results 
 As shown in Figure 3.1, 871 patients were identified as having an ICU admission 
with a concurrent positive culture for MRSA during the specified ICU admission. 
Following application of the exclusion criteria, 449 patients were available for analysis. 
Of these patients, 103 (22.9%) received a loading dose while 346 (77.1%) did not. Patient 
demographics for the cohort are shown in Table 3.1. The cohort consisted primarily of 
patients on medical services with approximately half of MRSA cases isolated from 
respiratory cultures. Approximately 3/4th of the cohort required mechanical ventilation 
and 1/3rd required vasopressor support at the time of vancomycin initiation. Patients were 
well-matched in terms of baseline characteristics between the two groups. Patients in the 
loading dose group received higher initial doses on a mg (1500 [1250-1750] vs. 1250 
[1000-1500]; p<0.001) and a mg/kg actual body weight basis (21 [20-22] vs. 16 [15-18]; 
p<0.001) compared to the no loading dose group. Patients classified as receiving a 
loading dose tended to weigh less than patients in the no loading dose group (68 [61-85] 
kg vs. 80 [66-97] kg; p<0.001). Only one patient received an initial vancomycin dose 
greater than 2 grams. All patients were administered vancomycin via intermittent 
infusion.  
 There was no difference in the percentage of patients experiencing clinical failure 






no significant difference between groups in any component of the composite outcome 
(Table 3.2). No differences were noted between groups in any of the secondary 
outcomes, including all-cause ICU mortality, AKI, or duration of vasopressor or 
mechanical ventilatory support. The first serum vancomycin trough concentration was 
slightly higher in the loading dose group, but this did not reach statistical significance 
(15.6 [11.0-24.4] mcg/mL vs. 14.0 [9.5-21.0] mcg/mL; p=0.056). There were no 
differences in WBC or maximum temperature in days 2-5 following the initiation of 
vancomycin (Table 3.3, Figure 3.2). In a simple competing risk regression model with 
death as a competing event, use of a loading dose was not associated with time to ICU 
discharge from vancomycin initiation (Subdistribution hazard ratio 1.09; 95% confidence 
interval 0.86-1.40). The cumulative incidence function is shown in Figure 3.3. In the 
subgroup of patients with isolated MRSA bacteremia, there was no difference in clinical 
failure between the loading dose and no loading dose groups: 30/34 (88.2%) vs. 63/80 
(78.8%); p=0.232. Similarly, in patients with MRSA respiratory cultures (with or without 
bacteremia), there were no differences between loading dose and no loading dose groups: 
47/69 (68.1%) vs. 188/265 (70.9%); p=0.647.  
In exploratory analyses of the primary outcome, the vancomycin dose (in mg/kg 
actual body weight) was assessed in quartiles rather than a dichotomous variable and 
there were no significant differences in the frequency of clinical failure (p=0.794; Table 
3.4).  Similarly, when initial doses of ≥ 1,750 mg were compared with doses <1,750 mg, 
there was no difference in clinical failure between the two groups (p=0.485; Table 3.5). 






(expressed in mg/kg as a continuous variable) was not associated with clinical failure: 
odds ratio (OR) 0.98 (95% confidence interval (CI) 0.91-1.06) (Table 3.6).  
3.4 Discussion 
This represents the first study to our knowledge to assess clinical outcomes 
associated with vancomycin loading doses recommended by consensus guidelines in 
critically ill patients with MRSA infection,23 and the largest study of vancomycin loading 
doses in any patient population. While the ideal design to answer this clinical question is 
a randomized controlled trial, given the literature that every hour delay in antibiotics in a 
patient with sepsis is associated with a 7.6% reduction in survival,40 including similar 
literature in S. aureus bacteremia specifically,84 obtaining informed consent during this 
window for a definitively large study in critically ill patients is likely to hinder such a 
trial ever being done, particularly for confirmed MRSA infection rather than all patients 
receiving empiric vancomycin.  
A randomized controlled trial of vancomycin loading doses in the emergency 
department showed that a loading dose of 30 mg/kg vs. 15 mg/kg resulted in higher 
trough values at 12- and 24- hours, but not by 36-hours, with no significant difference in 
AKI or clinical outcomes between the two groups.85 Similarly, other observational 
studies have shown an association between loading doses and higher target attainment of 
initial trough values without increasing the risk of AKI,86,87 although improved target 
trough attainment is not consistent across the literature.78,88 Similar to other studies, we 
did not observe any increased risk of AKI with use of a vancomycin loading dose.85,86  
Particularly with updated consensus guidelines recommending AUC assessment at this 






loading doses to trough attainment as justification for use of a particular dosing strategy 
deserves reevaluation. Thus, there is an increasing importance to evaluate clinical 
outcomes regarding the decision to administer a loading dose.  
One small cohort study found an association of vancomycin loading doses (≥ 20 
mg/kg) with clinical response, as defined by survivors with a ≥ 30% reduction in WBC 
count or C-reactive protein, or decline in fever over 48-72 hours; however, the number of 
MRSA cases from the cohort studied was relatively small.78 In a larger study of MRSA 
bacteremia, loading doses (≥  20 mg/kg) were not associated with treatment failure; 
however, in a post-hoc analysis where loading doses were reclassified as ≥ 1,750 mg, a 
protective effect of loading doses was noted.77 In both studies, loading doses were not 
associated with nephrotoxicity.77,78 Of note, critically ill patients were not the focus of 
these prior studies, and ICU patients comprised approximately 25% of the cohort.77 Our 
study did not find a benefit of loading doses on any of the distinct outcomes that we 
included in the primary composite outcome, nor when assessed by site of infection as a 
subgroup analysis. Similarly, there was no signal of benefit noted in the sensitivity 
analysis examining quartiles of loading doses, the reclassification of loading doses as 
1,750 mg or higher, or in the multivariable logistic regression model evaluating initial 
dose on a mg/kg basis as a continuous variable.  
As noted previously, a recent survey of vancomycin dosing practices in critically 
ill patients revealed that a lack of clinical outcome data, concerns of nephrotoxicity, and 
time delay of admixed custom doses from the pharmacy (in the case of a loading dose) 
vs. pre-mixed drug from automated dispending cabinet limited application of loading 






risk of AKI, even in critically ill patients with multiple risk factors for AKI. However, the 
data also suggest no clinical benefit of loading doses even in confirmed MRSA infections 
in critically ill patients, thus supporting the noted clinician hesitation. Indeed, given the 
increase in mortality with every hour delay in antibiotic therapy,40,84 our study supports 
the notion that therapy should not be delayed for dose customization to meet the specified 
loading dose criteria. This finding not only applies to emergency departments, post-
anesthesia care units, and other ICU triage areas in resource-intensive healthcare settings, 
but may also be a relevant consideration to care provisions in lower resource-intensive 
settings where dose customization for loading doses may be limited. Although the 
mechanistic explanation of our findings is less clear for patients with bacteremia, the 
relatively poor ability of vancomycin to concentrate in pulmonary tissue, particularly 
after a single dose, may explain the lack of difference in clinical outcomes observed in 
our study.89 Additionally, considering the literature associating a delay in second dose of 
antibiotics for patients admitted from the emergency department with sepsis with 
outcomes including mortality,90 our study suggests that the initial, loading dose of 
vancomycin may not significantly influence clinical outcomes in critically ill patients, 
and a greater emphasis be placed on ensuring timely initiation of subsequent doses to 
ensure appropriate efforts to attain goal AUC:MIC targets for the initial 24 hour period.  
 Strengths of our study included the large sample size, which was sufficiently 
powered to determine differences in clinical failure. We built on previous literature by 
studying only confirmed cases of MRSA and expanding on the study of pharmacokinetic 
outcomes to clinical outcomes of this patient population. Our definition of clinical failure 






objectively, thus not relying on subjective assessments such as clinical resolution.77,78 
Anticipating that detecting a difference in an outcome such as ICU length of stay or 
vasopressor duration would require several fold additional patients, the outcome of 
clinical failure is sensitive to surrogate outcomes such as WBC and temperature changes 
over time that may have seen more immediate effects from the loading dose, if present. 
The two groups of patients were similar in terms of severity of illness, kidney disease, 
and other pre-identified factors that might have predisposed to receipt of a loading dose 
or clinical outcome. We also included multiple types of infections commonly afflicting 
critically ill patients.   
 Our study also has noted limitations, including the retrospective, non-randomized, 
and single center design. Due to vancomycin dosing practices at the institution, we are 
not able to make any inferences about the clinical benefits of loading doses beyond 2,000 
mg as only one patient received a > 2,000 mg loading dose. However, a dose cap of 2,000 
mg was the most commonly reported dose cap in a prior study of vancomycin dosing 
practices among critical care pharmacists suggesting this practice is widespread.75 
Relevant to this study, any patient over 100 kg was therefore essentially ineligible to be 
categorized as having received a loading dose. Accordingly, whether or not relatively 
larger loading doses (up to 3,000 mg as maximally defined in current consensus 
guidelines)23 are associated with any clinical benefit remains unknown at this time, 
although the lack of dose response noted in the exploratory analysis of loading dose by 
quartiles would suggest against this. Our study design also excluded patients weighing ≥ 
125 kg, thus our results may not be directly applicable to obese patients. The difference 






not as drastic as would have been the case if higher loading doses were used in our study. 
The loading dose group received an additional 5 mg/kg (or 250-500 mg typically). While 
dichotomization of information can have drawbacks, use of a loading dose or not is 
typically a dichotomous decision clinically. Additionally, the lack of signal in the quartile 
analysis and in the multivariable regression where initial dose was analyzed as a 
continuous variable supports the findings that initial dose does not appear to impact 
clinical failure. We also did not estimate or measure vancomycin AUC in these groups as 
a result of the loading dose, or in subsequent dosing intervals, and thus are unable to 
directly compare vancomycin AUC with these clinical outcomes. The known variability 
in vancomycin pharmacokinetics in critically ill patients makes it possible that patients in 
this study may have not achieved adequate AUC with the loading doses thus explaining 
the lack of clinical benefit observed. For example, a significant number of these patients 
may have had AKI upon admission or been actively fluid resuscitated at the time of 
vancomycin loading dose, which would have increased the Vd and may have influenced 
the ability to achieve the target exposure with the vancomycin doses observed in the 
study. More patients had respiratory infections than bacteremia, thus if there was a 
differential effect of loading doses given the site of infection, we may have been 
underpowered to detect it. Finally, although patients appeared to be well-matched based 
on identified characteristics, we cannot rule out residual confounding and its effects.  
3.5 Conclusion 
 In critically ill patients with MRSA infection cultured from the blood or 






weight) was not associated with any differences in clinical failure, mortality, ICU length 






























Table 3.1 Baseline Demographics  






Age (years) 54 (38-66) 57 (45-68) 0.102 
Sex (% male) 58 (56.3%) 198 (57.2%) 0.869 
Culture Site   0.099 
Blood 34 (33.0%) 80 (23.2%)  
Respiratory 55 (53.4%) 199 (57.7%)  
Both 14 (13.6%) 66 (19.1%)  
Chronic Kidney Disease (%) 8 (7.8%) 41 (11.9%) 0.243 
End Stage Renal Disease (%) 7 (6.8%) 23 (6.7%) 0.958 
Service (% medical) 80 (77.7%) 234 (67.6%) 0.051 
Minimum inhibitory concentration 
(mcg/ml)a 
1 (1-1) 1 (1-1) 0.352 
Long Term Indication for MRSA 
Treatmentb  
12 (11.7%) 25 (7.2%) 0.216 
Weight (kg) 68 (61-85) 80 (66-97) <0.001 





Initiation vancomycin dose (mg/kg actual 
body weight) 
21 (20-22) 16 (15-18) <0.001 
Number of concurrent nephrotoxins 
within first 5 days 
1 (0-2) 1 (1-2) 0.441 
Vancomycin therapy duration (days) 6 (3-12) 6 (3-11) 0.843 
At Time of Vancomycin Initiation     
White blood cell count (x103/mm3) 15 (10-21) 13 (9-19) 0.150  
Blood urea nitrogen (mg/dl) 23 (15-41) 26 (15-41) 0.625 
Serum creatinine (mg/dl) 1.1 (0.7-1.6) 1.0 (0.7-1.7) 0.902 





Sequential Organ Failure Assessment 
score 
8 (5-10) 7 (5-10) 0.674 
Pitt Bacteremia Score 5 (4-7) 5 (3-7) 0.607 
Requirement for vasopressor support (%) 31 (30.1%) 105 (30.4%) 0.961 
Mechanical ventilation (%) 77 (74.8%) 254 (73.6%) 0.818 
Lactate (mmol/L)c 1.8 (1.1-3.3) 1.6 (1.1-3) 0.586 
aAvailable for 295 patients 
bLong-term indication defined as ≥ 4 weeks of therapy 
















Primary Outcome    
Clinical failure (%) 77 (74.8%) 252 (72.8%) 0.698 
Death within 30 days (%) 20 (19.4%) 77 (22.3%) -- 
Blood cultures positive ≥ 7 days (%) 12 (11.7%) 16 (4.6%) -- 
WBC >12 x103 /mm3 after 5 days 28 (27.2%) 93 (26.9%) -- 
Persistent temperature >100.4° F after 5 
days 
8 (7.8%) 36 (10.4%) -- 
Substitution/addition of alternative 
treatment 
9 (8.7%) 30 (8.7%) -- 
Secondary Outcomes    
All-cause mortality in ICU (%) 21 (20.4%) 87 (25.1%) 0.321 




9.5 (4.9-17.4) 0.880 
Acute kidney injury within 5 days of 
vancomycin initiation (%)a 
20 (20.2%) 59 (17.8%) 0.765 
Duration of vasopressor support (days)b 3 (2-5) 3 (2-6) 0.793 
Duration of mechanical ventilation (days)c 8.5 (4.3-17) 9 (4-20) 0.632 
First vancomycin serum trough 
concentration (mcg/ml)d  
15.6 (11.0-
24.4) 
14.0 (9.5-21.0) 0.056 
WBC = white blood cell count  
aPatients with End Stage Renal Disease excluded from assessment  
bAvailable for the 136 patients requiring vasopressor support at vancomycin initiation 
cAvailable for the 331 patients requiring mechanical ventilation at vancomycin initiation  





















WBC (x103 /mm3)    
Day 2 11.8 (8.9-
17.3) 
12.5 (8.9-18.7) 0.814 
Day 3 10.8 (7.9-
15.7) 
11.9 (8.8-17.9) 0.254 
Day 4 11.1 (7.9-
15.8) 
11.3 (7.7-16.5) 0.936 
Day 5 10.7 (7.6-14) 11 (7.4-16.4) 0.446 
    
Temperature (°F)    



























Table 3.4 Primary Outcome Assessed by Quartiles of Initial Dose (mg/kg) 
Initial Dose Quartile 






1st quartile (7.9-15.1) 29 (25.7%) 84 (74.3%) 
2nd quartile (15.1-17.2) 34 (30.4%) 78 (69.6%) 
3rd quartile (17.2-19.3) 29 (25.9%) 83 (74.1%) 









Table 3.5 Primary Outcome with Loading Dose Categorized as ≥ 1,750 mg 
Outcome Loading Dose 
(n=100) 
No Loading Dose 
(n=349) 
p-value 


























Table 3.6 Multivariable Logistic Regression Model for Clinical Failure   





First vancomycin dose (mg/kg) 0.98 (0.91-1.06) 0.617 
Age (years) 1.01 (0.99-1.02) 0.418 
Sex (male vs. female) 0.73 (0.44-1.21) 0.226 
Infection Site (compared to blood alone)   
Respiratory 0.41 (0.21-0.81) 0.011 
Concomitant blood and respiratory 0.47 (0.21-1.08) 0.074 
End stage renal disease 0.17 (0.05-0.56) 0.003 
Chronic kidney disease 1.06 (0.45-2.46) 0.899 
ICU service (surgical vs. medical) 1.20 (0.70-2.07) 0.503 
Day 1 white blood cell count (x103/mm3) 1.08 (1.04-1.12) <0.001 
Day 1 blood urea nitrogen (mg/dl) 0.98 (0.97-0.99) 0.016 
Day 1 serum creatinine (mg/dl) 1.35 (1.04-1.76) 0.023 
Day 1 maximum temperature (°F) 0.97 (0.85-1.10) 0.597 
Sequential Organ Failure Assessment score 1.23 (1.09-1.37) <0.001 
Requirement for vasopressor support (%) 0.61 (0.31-1.21) 0.156 
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4.1 Introduction  
Revised consensus guidelines for therapeutic drug monitoring (TDM) of 
vancomycin recommend a shift from trough-based monitoring to area-under-the-curve 
(AUC) monitoring, with a daily goal (assuming a minimum inhibitory concentration 
(MIC) of 1 mg/L) of 400-600 mg·h/L.23 Failure to obtain sufficient AUC/MIC target 
attainment early in therapy (days 1 and 2) has been associated with treatment failure in 
Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and endocarditis.73,91 On 
the other hand, AUC values greater than 600-650 mg·h/L are associated with acute 
kidney injury (AKI).37,92 Critically ill patients with infection are already susceptible to 
AKI and often show altered pharmacokinetic changes that can markedly impact 
vancomycin’s volume of distribution (Vd) and clearance (CL).93 Thus, approaches to 
optimize vancomycin AUC target attainment early in therapy for critically ill patients 
with confirmed or suspected MRSA infection are needed.  
As an early adopter of AUC-guided vancomycin dosing, our center has several 
years of experience with AUC monitoring of vancomycin in a wide variety of patient 
populations.94 We developed a protocol using serum vancomycin concentrations obtained 
following the first dose of vancomycin to calculate patient-specific pharmacokinetic 
parameters used for further dosing as one approach to target precision dosing of 
vancomycin in high-risk patients, including the critically ill. Alternatively, empiric 
dosing based on population pharmacokinetic estimates was also available as a method to 
develop initial vancomycin regimens targeted at AUC values. The use of first-dose 
kinetics to guide dosing and the subsequent impact on vancomycin trough attainment has 






approaches allowed a unique opportunity to compare dosing strategies of vancomycin on 
AUC target attainment in critically ill adults.  
We sought to test a personalized dosing strategy, using two concentrations 
following the initial dose of vancomycin and employing first-dose pharmacokinetic 
calculations to guide subsequent dosing, versus dosing with population pharmacokinetic 
estimates on the outcome of vancomycin AUC target attainment assessed at steady state 
(SS) in critically ill patients receiving vancomycin.  
4.2 Methods 
4.2.1 Study Design 
The University of Kentucky Chandler Medical Center is an 865-bed tertiary care 
referral center for the state and surrounding region. For inpatients, all scheduled 
vancomycin therapy is dosed per pharmacist protocol approved by the Pharmacy and 
Therapeutics Committee. Pharmacists may alter vancomycin dosages, order vancomycin 
levels, and order laboratory tests for monitoring such as a basic metabolic panel for 
serum creatinine. In September of 2017, in anticipation of vancomycin TDM guideline 
changes, the monitoring of vancomycin was changed from trough-based to AUC as 
previously described.94 
In a retrospective cohort design, all patients admitted to the medical intensive care 
unit (MICU) from September 2017 to June 2019 with at least two vancomycin serum 
concentrations ordered to calculate AUC at SS and receiving > 1 dose of intravenous 
vancomycin were assessed for inclusion in the study. Patients were excluded if serum 
concentrations were obtained following the first dose but no SS levels (therapy was 






dosing due to AKI or the receipt of renal replacement therapy, if they received 
vancomycin at an outside hospital prior to transfer (as first-dose vancomycin 
concentrations would not have been able to be obtained), or if the vancomycin 
concentrations were drawn incorrectly (i.e. drawn from non-flushed catheter) or 
laboratory error was suspected by the assessing pharmacist as determined by documented 
records.  
This resulted in a cohort of critically ill patients that received vancomycin with at 
least two SS levels obtained for AUC calculation. From this cohort, two groups were 
identified: those patients in whom vancomycin concentrations were obtained following 
the first dose to guide subsequent dosing (first-dose kinetics) and those patients dosed 
based on population estimates (empiric dosing). Accordingly, the first-dose kinetics 
group had four vancomycin concentrations drawn (two for first-dose pharmacokinetic 
calculation and two at SS for AUC calculation) and the empiric dosing group had two 
concentrations assessed (at SS for AUC calculation). The primary outcome was goal 
AUC target attainment (defined as 400-600 mg·h/L) at SS. Secondary outcomes included 
AKI between the first-dose kinetics and empiric dosing groups (assessed starting at the 
time SS levels were drawn and up to 48 hours following SS levels using the serum 
creatinine component of the Kidney Disease Improving Global Outcomes [KDIGO] 
criteria79) and a comparison of pharmacokinetic parameters (elimination rate constant 
(ke), Vd, CL,) between the time of first dose and SS in the first-dose kinetics group. 
Pharmacokinetic parameters and creatinine clearance were also compared between the 
first-dose kinetics group and empiric dosing group at steady state to ensure 






vancomycin doses, infusion times, intervals, and time stamps necessary to confirm 
calculated AUC. Demographic data collected include patient age, sex, weight, height, 
serum creatinine, serum blood urea nitrogen, Sequential Organ Failure Assessment 
(SOFA) score80, and receipt of concurrent nephrotoxins from initiation of vancomycin up 
to 48 hours following SS (defined as angiotensin converting enzyme inhibitors, acyclovir 
(intravenous), aminoglycosides, amphotericin B, angiotensin receptor blockers, colistin, 
foscarnet, nonsteroidal anti-inflammatory drugs, polymyxin B, 
sulfamethoxazole/trimethoprim, tacrolimus (intravenous), and piperacillin /tazobactam). 
Creatinine clearance (CrCl) was estimated with Cockcroft-Gault95 or Salazar-Corcoran96 
if greater than 125% of ideal body weight. The electronic medical record was manually 
reviewed to obtain the necessary data and confirm accuracy of all calculations. The study 
was approved by the Institutional Review Board at the University of Kentucky.  
4.2.2 Vancomycin Dosing Protocol  
During the study period, two options existed for calculation of empiric 
vancomycin dosing for patients with stable renal function. One option allowed for 
assessing two serum vancomycin concentrations following the first dose and using first-
dose pharmacokinetics to develop a personalized dosing regimen based on the patient’s 
established pharmacokinetic parameters. This approach was primarily used in the MICU 
as opposed to other units in the hospital based on pharmacist preference. Alternatively, 
population estimates for Vd and ke could be used to develop a regimen anticipated to 
produce a daily AUC of 400-600 mg·h/L (Appendix 2). A loading dose of 25 mg/kg is 
recommended for all patients with serious infections in the institutional protocol 






recommended target when designing a regimen, assuming as consensus guidelines 
recommend, an MIC of 1 mg/L.23 The decision to order vancomycin levels following the 
first dose to guide subsequent dosing or to use population estimates to inform an initial 
maintenance dose is at the discretion of the pharmacist ordering the initial dosing of 
vancomycin. Two vancomycin concentrations at SS, either peak/trough or two random 
levels following the SS dose, are included in the dosing protocol to calculate the AUC. 
SS levels are recommended around the 4th dose of vancomycin, but pharmacists can use 
their judgement to assess earlier or later based on clinical characteristics or to avoid 
vancomycin level assessment during sleeping hours. Using these concentrations, we used 
first-order pharmacokinetic equations as recommended by consensus guidelines to 
calculate pharmacokinetic parameters and AUC values (Appendix 2).23,97,98  
4.2.3 Statistical Analysis 
Patient demographic data are reported as proportions or means/medians, as 
appropriate per the distribution. AUC target attainment and nephrotoxicity between 
groups were evaluated using the Chi-Square test. For the analysis of AUC target 
attainment, logistic regression was used to adjust for any significant differences in 
relevant baseline characteristics between the two cohorts that may have served as 
confounders as assessed by study investigators. Continuous data between the first-dose 
kinetics and empiric dosing group were compared using the independent samples t-test or 
Wilcoxon rank-sum test depending on the distribution. When comparing CrCl or 
pharmacokinetic parameters within the same group from baseline to SS, the Wilcoxon 
signed-rank test was used. Data were analyzed using Stata (StataCorp. 2019. Stata 







 Of 160 patients admitted to the MICU meeting potential inclusion criteria during 
the study period, 94 were excluded, with the most common reasons being AKI (n=64) or 
therapy not continued long enough for SS level evaluation (n=20) (Figure 4.1). Sixty-six 
patients met the full inclusion criteria: 29 patients with first-dose kinetics and 37 patients 
with empiric vancomycin dosing. All patients received intermittent intravenous infusions 
of vancomycin.  
 Baseline characteristics were well-balanced between the two cohorts (Table 4.1), 
with the only significant differences being that patients in the first-dose kinetics group 
received a slightly higher initial dose of vancomycin compared to the empiric dosing 
group (2043 ± 449 mg vs. 1568 ± 499 mg; p<0.001) and the time from the first dose of 
vancomycin to the first steady state concentration assessment was slightly longer in the 
first-dose kinetics group (60 (50-80) hours vs. 47 (37-67) hours; p=0.018) compared to 
the empiric dosing group. Importantly, patients were well-matched on age, baseline renal 
function (including CrCl), severity of illness, and receipt of concurrent nephrotoxins.  
 The primary outcome, target AUC target attainment at SS (400-600 mg·h/L), was 
achieved in 58.6% of first-dose kinetics patients compared to 32.4% with empiric dosing 
(p=0.033). For those not meeting the desired AUC goal, patients in the empiric dosing 
group were more likely to be subtherapeutic (40.5%) compared to the first-dose kinetics 
group (3.5%). First-dose kinetics patients, when not achieving AUC target attainment, 
were more likely to be supratherapeutic compared to the empiric dosing group (37.9% vs. 
27.0%). Correspondingly, the median AUC, estimated peak, and trough concentrations 






minimum and maximum AUC values were numerically more extreme, and the overall 
variability in AUC at SS was greater (coefficient of variation 40.7% vs. 26.1%), in the 
empiric dosing group compared to the first-dose kinetics group (Figure 4.2). 
Pharmacokinetic parameters and CrCl at steady state were similar between the two 
groups (Table 4.2). There was no difference between groups in AKI assessed from SS up 
to 48 hours following collection of vancomycin concentrations at SS.  
In simple logistic regression, the use of first-dose kinetics vs. empiric dosing was 
associated with a 2.95 greater odds of AUC target attainment at SS (OR 2.95 95% CI 
1.08-8.10). When adjusted for initial vancomycin dose and time to steady state 
concentration assessment (neither of which were significantly associated with AUC target 
attainment in the model), similar results were obtained with a 3.33 greater odds for SS 
AUC target attainment with first-dose kinetics (OR 3.33 95% CI 1.03-10.72) compared to 
empiric dosing.  
The estimated CrCl increased in both groups from the time of the first dose of 
vancomycin to SS: from 107 (66-143) to 110 (78-156) mL/min in the first-dose group 
(p=0.094 via pair-wise comparison) and from 109 (73-151) to 141 (98-179) mL/min in 
the empiric dosing group (p<0.001 via pair-wise comparison). In the group of patients 
with first-dose kinetics, calculated pharmacokinetic parameters were similar between the 
time of first-dose and SS, with the only exception calculated CL which was greater at the 
time of first-dose than at SS (Table 4.3).  
4.4 Discussion 
 The AUC/MIC ratio is recommended in consensus guidelines as the 






when treating MRSA infections.23 This parameter, related to both efficacy and safety of 
vancomycin, has particular relevance to critically ill patients who are at high risk of 
complications from MRSA as well as at high risk of AKI with multiple nephrotoxic risk 
factors. We showed that patients dosed using a personalized dosing approach with first-
dose pharmacokinetics to drive subsequent dosing experienced greater AUC target 
attainment at SS versus empiric dosing. Although the study was observational in design, 
the two groups were well-balanced except for two parameters that differed by clinically 
questionable magnitudes: initial dose of vancomycin differed by approximately 500 mg 
and time from vancomycin initiation to SS concentration assessment differed by 
approximately 12 hours. We suspect the longer time to SS concentration evaluation may 
have been due to pharmacist confidence in the dosing regimen selected given the first-
dose pharmacokinetic approach and willingness to wait longer to assess as compared to 
empiric dosing. Even when adjusted for these differences as potential confounders, the 
use of first-dose kinetics was consistently associated with a greater likelihood of AUC 
target attainment at SS. As early and accurate AUC target attainment is increasingly 
recognized as important in MRSA infections, this approach offers one way to increase the 
likelihood of AUC target attainment as compared to empiric dosing.  
Casapao and colleagues, in a retrospective study of patients with MRSA infective 
endocarditis, concluded that failure to obtain a day 1 vancomycin AUC/MIC of at least 
600 was associated with an increased risk of treatment failure, defined as persistent 
bacteremia (≥ 7 days) or 30-day attributable mortality.91 Lodise and colleagues similarly 
found that day 1 and 2 vancomycin AUC/MIC thresholds (values dependent on MIC 






bacteremia ≥ 7 days, or recurrence.73 The association of vancomycin AUC with AKI is 
relevant in the early therapy window as well. In a recent meta-analysis, a vancomycin 
AUC < 650 mg·h/L on day 1 or 2 was associated with less AKI.37 Thus, there is a critical 
need, particularly in an at-risk population such as critically ill patients, for early and 
accurate attainment of vancomycin AUC to optimize the chance of clinical efficacy and 
minimize the risk of AKI.  
The approach of using patient-specific pharmacokinetic parameters obtained from 
two serum concentrations following the first dose in designing regimens for vancomycin 
has produced mixed results.42,43 In critically ill patients, Truong and colleagues 
demonstrated that using patient-specific pharmacokinetic parameters derived from two 
serum concentrations following the first dose of vancomycin resulted in greater goal 
trough concentrations compared to those patients dosed without first-dose 
pharmacokinetic monitoring.43 Conversely, in pediatric patients, first-dose monitoring of 
vancomycin did not significantly shorten the time to achieve target serum drug 
concentrations.42 These prior studies have used trough levels as target attainment, which 
limits application to some extent in the era of vancomycin AUC-guided dosing. 
Therefore, we sought to study AUC target attainment at SS in critically ill patients dosed 
with first-dose kinetics versus empiric dosing.  
Similar to Truong et al,43 we observed greater target attainment in the first-dose 
group compared to empiric dosing. Neither study demonstrated a reduction in the 
incidence of AKI with this approach, although both studies were likely underpowered for 
the outcome of AKI. Our pharmacokinetic parameters calculated and their variability are 






Pharmacokinetic parameters in this patient population were generally similar between the 
start of vancomycin and SS, further bolstering the validity of using first-dose 
pharmacokinetic calculations in critically ill patients with relatively stable renal function. 
This approach was shown to be beneficial for vancomycin, but may have utility with 
other antibiotics as well such as beta-lactams99 given the time-critical nature of 
pharmacokinetic/pharmacodynamic target attainment in critically ill patients. 
Additionally, this approach may be suitable for high risk patients admitted to non-ICU 
services. It was recently demonstrated that vancomycin AUC target attainment in patients 
with MRSA complicated skin and soft tissue infections was associated with timely 
clinical success and a trend toward a shorter hospital length of stay.100 Thus, our results 
could be extrapolated outside of the critically ill patient population to a broader cohort of 
hospitalized patients with MRSA infection that would benefit from early and precise 
AUC target attainment.  
 While this approach demonstrated success in producing goal SS AUC target 
attainment with a number needed to treat of 4, there are challenges to using this approach 
that deserve mention. First, if this approach was applied universally, a number of patients 
would receive therapeutic drug monitoring after the first dose of vancomycin that may go 
on to receive less than 48 hours of vancomycin therapy. Assuming a patient continues to 
receive vancomycin until concentrations are assessed at SS, this approach results in 4 
vancomycin serum concentrations within a period of days. These costs are combined with 
the labor costs of pharmacokinetic evaluation, with the realization that overnight 
evaluation of levels may be required depending on the timing of vancomycin initiation. 






of vancomycin concentrations may not exist equally at all hospitals. The use of Bayesian 
dose optimization tools may help limit the number of required samples if using this 
approach. The use of first-dose kinetics also requires a presumption of stable renal 
function at the time of first-dose kinetics and anticipation that renal function will be 
similar at SS, which may be difficult to predict. Although CrCl increased numerically in 
both the first-dose kinetics and empiric dosing groups, it was relatively stable from a 
clinical standpoint from baseline to SS. As such, patients targeted for this approach 
would need to have presumed stable renal function at the time of vancomycin initiation 
and anticipated to maintain stable renal function by the time of SS evaluation. 
Augmented renal clearance has also been noted in sepsis and critically ill patients, which 
may influence first-dose pharmacokinetic calculations if present and risk over-estimating 
clearance.101,102 As noted, a significant number of patients were excluded due to active 
AKI, which limits the approach of first-dose kinetics. While empiric dosing was more 
likely to provide subtherapeutic AUC exposure compared to first-dose kinetics, Figure 
4.2 shows a cluster of AUC exposures in the empiric group between 350-400 mg·h/L, 
which for empiric therapy with no MRSA isolated may be clinically appropriate. 
However, for severe, confirmed MRSA infection, an AUC of 400-600 mg·h/L would be 
desired. A high-risk population, either at risk of MRSA isolation or with multiple AKI 
risk factors, might be identified to benefit most from the patient-specific dosing afforded 
from obtaining vancomycin serum concentrations following the first dose. This approach 
is particularly feasible as rapid diagnostics and clinical prediction rules for MRSA 
continue to be refined. Despite the improved AUC target attainment at SS compared to 






58.6%, which identifies the need for greater precision dosing mechanisms for 
vancomycin in critically ill patients, potentially including use of continuous infusion.70 
Over one-third of patients in the first-dose kinetics group had AUC values above goal at 
SS, which may be due to acute changes in pharmacokinetics in critically ill patients. This 
is another area where application of Bayesian technology may assist with fluctuating 
renal function that may not meet traditional AKI criteria.  
 Our study is not without limitations worthy of discussion. First, this study’s 
sample size was known to be small in the design phase due to the finite population of 
patients with first-dose kinetics and steady state levels, thus the study was underpowered 
for AKI detection. Clinical efficacy outcomes were not assessed as it was recognized 
only a fraction of these patients would have true MRSA infection. Second, although the 
groups were generally similar at baseline, the initial loading dose was slightly higher in 
the first-dose kinetics group and more time had passed in the first-dose group when SS 
concentrations were assessed. Prior studies report mixed results on the impact of initial 
loading dose on target attainment at steady state,87,103 and the difference between groups 
was less than 500 mg, which may not be clinically relevant 2-3 days later when SS 
concentrations are assessed. Additionally, the effect estimate of using the first-dose 
kinetics strategy was similar when adjusting for initial dose and time to SS concentrations 
in the logistic regression model. The lower initial dose could indicate non-compliance 
with institutional dosing protocols in the empiric dosing group. The appropriateness of 
initial dosing in the empiric group was not assessed in our group, and we acknowledge 
that clinical judgement may influence a pharmacist’s dosing recommendations at the 






groups between baseline and SS, but was greater in the empiric dosing group, which may 
partially explain the greater subtherapeutic AUC values in the empiric dosing group vs. 
the first-dose kinetics group. There are also are a number of inherent assumptions in 
using these pharmacokinetic equations, such as the assumption that serum concentrations 
are obtained at least one half-life apart as well as the fact that two compartment 
elimination is sometimes possible to observe, particularly if the initial post-dose level is 
drawn too soon. These assumptions may have contributed to the AUC target attainment 
in the first-dose kinetics group not being higher. Finally, unmeasured confounders could 
have biased the results if systemic differences existed between first-dose kinetics and 
empiric dosing groups aside from pharmacist preference at the time of initial dosing.  
4.5 Conclusion 
A dosing strategy using two vancomycin serum concentrations following the first 
dose and calculating personalized pharmacokinetic parameters to guide subsequent 
dosing is associated with greater AUC target attainment at SS compared to empiric 
dosing of vancomycin in critically ill adults. Future applications of this strategy to other 
antibiotics in the ICU, non-ICU patient populations, identification of patients most likely 
to benefit, and comparison to Bayesian approaches using concentrations after the first 











Table 4.1 Patient Demographics 
a Calculated using Cockcroft-Gault or Salazar-Corcoran (if weight greater than 125% of ideal 

















Age (years) 54.0 ± 17.2 46.6 ± 14.3 0.060 
Sex (% male) 15 (51.7%) 20 (54.1%) 0.851 
Weight (kg) 84.3 (72.5-106.8) 80.0 (60.4-94.2) 0.165 
Initial dose (mg) 2043 ± 449 1568 ± 499 <0.001 
Expressed as mg/kg ABW 24 (22-25) 19 (16-23) <0.001 
Serum creatinine at 
vancomycin initiation (mg/dL) 
0.89 ± 0.32 0.91 ± 0.37 0.813 
Blood urea nitrogen at 
vancomycin initiation (mg/dL) 
18 (13-30) 19 (13-25) 0.660 
Estimated creatinine clearancea 
at vancomycin initiation 
(mL/min) 
107 (66-143) 109 (73-151) 0.841 
SOFA score 7.4 ± 3.0 7.3 ± 2.7 0.884 
Total daily maintenance dose 
(mg) 
2629 ± 820 2426 ± 1027 0.387 
Receipt of concurrent 
nephrotoxins (%) 
23 (79.3%) 24 (64.9%) 0.198 
Time from first dose to SS 
concentration assessment 
(hours) 






Table 4.2 Study Outcomes 





Achievement of target AUC 
at steady state (%) 
17 (58.6%) 12 (32.4%) 0.033 
Below 400 mg·h/L 1 (3.5%) 15 (40.5%) --- 
Above 600 mg·h/L 11 (37.9%) 10 (27.0%) --- 
AUC at steady state 
(mg·h/L) 
575 (491-722) 438 (379-650) 0.006 
Acute kidney injury (%) 4 (13.8%) 4 (10.8%) 0.713 
Estimated Trough 
Concentration (mg/L) 
16.4 (12.0-18.7) 11.5 (6.8-17.2)  0.020 
Estimated Peak 
Concentration (mg/L) 
36.4 (31.1-41.4) 32.1 (23.6-37.8) 0.049 
ke (hr-1) 0.078 (0.047-0.121) 0.070 (0.054-0.126) 0.647 
Half-life (hr) 8.9 (5.7-14.7) 9.9 (5.5-12.8) 0.647 
Volume of distribution (L) 54.6 (42.2-86.5) 
 
55.6 (39.7-87.8) 0.892 
Clearance (L/hr) 4.8 (3.4-5.5) 4.6 (3.1-6.5) 0.811 
Creatinine Clearance 
(mL/min) 
110 (78-156) 141 (98-179) 0.072 

















Table 4.3 Pharmacokinetic Parameter Comparison Between First-Dose and Steady State 
in the First-Dose Kinetics Group 





ke (hr-1) 0.084 (0.060-0.115) 0.078 (0.047-
0.121) 
0.122 
Volume of distribution (L) 64.0 (45.0-72.9) 54.6 (42.2-86.5) 0.804 
Volume of distribution 
(L/kg) 
0.70 (0.51-0.81) 0.58 (0.45-0.99) 0.689 
Clearance (L/hr) 5.0 (4.0-6.5) 4.8 (3.4-5.5) 0.012 





























































CHAPTER 5 VANCOMYCIN CONTINUOUS VERSUS INTERMITTENT 
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Vancomycin is one of the most commonly prescribed antibiotics in the inpatient 
setting, particularly in the intensive care unit (ICU), for empiric coverage of methicillin-
resistant Staphylococcus aureus (MRSA). Despite extensive clinical experience, a 
number of questions remain regarding its optimal use, including: pharmacokinetic 
(PK)/pharmacodynamic (PD) targets translated from experimental models which inform 
clinicians of optimal drug levels to maximize efficacy of the drug, ideal methods of 
administration, and techniques to minimize toxicities.62 The most clinically relevant 
adverse effect from vancomycin remains acute kidney injury (AKI), and the clinician 
must balance achieving relevant PK/PD targets with the risk of AKI. Particularly in the 
vulnerable critically ill patient facing many other kidney insults, the risk of vancomycin-
associated AKI may be even higher in this patient population.104 AKI rates with 
vancomycin are reportedly as high as 35% when prescribed with other antibiotics, as is 
commonly done in the ICU.38 Furthermore, AKI in hospitalized patients is associated 
with significant increases in mortality, length of stay, and health care costs 105. 
 Prior work attempting to summarize the effect of continuous versus intermittent 
vancomycin infusion on AKI in meta-analyses is limited by three main factors: 1.) 
including a broad mix of patient presentations vastly different from one another 
(outpatient antimicrobial therapy and ICU patients in the same evaluation) has 
subsequently lead to conflicting conclusions among meta-analyses, 2.) meta-analytic 
techniques using raw numbers from observational research rather than odds ratios which 
more accurately reflect adjustment for confounding factors in the individual studies (if 






an increasing trend of publications regarding continuous infusion vancomycin.56,57,106 We 
therefore conducted a systematic review and meta-analysis of continuous versus 
intermittent infusion vancomycin and the associated risk of AKI in critically ill adults. 
5.2 Materials and Methods 
5.2.1 Search Strategy and Study Selection 
With the assistance of an experienced medical librarian, we conducted a 
systematic search using PubMed/MEDLINE, CINAHL, Web of Science, International 
Pharmaceutical Abstracts, and Google Scholar from inception to June 2017. References 
of relevant articles and personal files were also included. A combination of search terms 
was used, including variants of the following: critical care, intensive care, vancomycin, 
continuous, and intermittent. We included randomized clinical trials or cohort studies 
(retrospective or prospective, including quasi-experimental) comparing AKI or 
nephrotoxicity between continuous and intermittent infusion of vancomycin in adult 
patients. We only included ICU patients as clearly identified in the study methods. We 
excluded studies comparing the two regimens in patients on continuous renal replacement 
therapy given the outcome of interest (AKI) had already occurred. Only peer-reviewed 
publications were included; conference proceedings were not considered for inclusion. 
Two authors independently assessed articles for inclusion, with discrepancies resolved 
via discussion among authors or with the assistance of a third author, if needed. The 
search was updated in September of 2019. The protocol is registered on PROSPERO 
2017:CRD42017053746 and reported according to the Preferred Reporting Items for 






5.2.2 Data Extraction, Risk of Bias, and Outcomes 
Data elements from included studies were extracted and confirmed by two authors 
using a standardized table. Variables included: year of study, study design, ICU type, 
infection type (pathogen and source), definition of AKI/nephrotoxicity, pharmacokinetic 
goal ranges for both infusion strategies, use of a loading dose, dosing regimen, age, 
weight, gender, baseline serum creatinine, mean/median daily dose and duration, and 
frequency of concomitant nephrotoxins.  
Risk of bias was assessed with the Cochrane Risk of Bias Assessment Tool for 
randomized clinical trials and with the Newcastle-Ottawa scale for observational 
studies.108,109 Two authors independently assessed risk of bias, with discrepancies 
resolved via discussion among investigators or with the assistance of a third author, if 
needed.  
The primary outcome was AKI/nephrotoxicity, as defined according to each 
study’s definitions. Mortality was assessed as a secondary outcome, as was % target 
attainment for the pharmacokinetic goal (typically a trough level for intermittent infusion 
and plateau level for continuous infusion) set by the dosing protocol in the study. Data 
were extracted for these binary outcomes as both counts as well as odds ratio (OR) with 
95% confidence intervals (CI). If an adjusted analysis was performed, the OR and 95% 
CI were extracted from the adjusted analysis reported for a study. If the data were 
presented as counts, the OR and 95% CI was manually calculated.  
5.2.3 Data Synthesis and Analysis 
Meta-analyses were performed using RevMan v5.3 (The Cochrane Collaboration, 






meta package.110 The risk of publication bias was assessed with the use of a funnel plot 
and Harbord test.111 The generic inverse variance method was used to pool ORs from 
each included study for AKI and mortality. The Mantel-Haenszel method was used for 
proportions with count data for percentage target attainment for the pharmacokinetic 
secondary outcome. Heterogeneity was assessed with the I2 statistic. Given the 
anticipated heterogeneity in study designs and definitions, a random effects model was 
selected as the most conservative approach.  
5.3 Results 
5.3.1 Search Results and Study Characteristics 
Following removal of duplicates from the search strategy, 311 unique citations were 
screened for inclusion. A large portion of these (n=121) were excluded for only 
evaluating one method of infusion strategy. Of the 29 studies remaining following 
application of the exclusion criteria, 6 studies did not meet criteria to be classified as 
studying critically ill patients. Of the 23 studies remaining, 11 met criteria for inclusion in 
the analysis of the primary outcome. Complete search results and identification of 
included studies are shown in Figure 5.1. 
 We identified 11 total studies published over a 23 year period, which evaluated 
2,123 patients for the primary outcome of AKI.54,55,71,112-119 Study characteristics, 
demographics, and definitions are provided in Table 5.1. Two studies were randomized 
trials, 3 were prospective observational, and 6 were retrospective cohort studies. 
Collectively, the studies investigated a wide range of ICU populations including medical, 
surgical, trauma, neurologic, cardiac, and burns. While some studies focused on a 






infections in the ICU setting. While the definitions of nephrotoxicity differed across 
study groups, all but 3 studies included an increase of serum creatinine by 50% from 
baseline as at least part of the definition.54,55,71,112-119 Dosing targets for single 
concentrations (continuous group) and troughs (intermittent) varied, but the most 
common recurring targets were 20-25 mg/L for continuous infusion and a trough of 15-
20 mg/L for intermittent dosing. Loading doses were more commonly noted in the 
continuous infusion group. Initial dosing regimens varied across studies as well, with 15 
mg/kg q8-12h being the most common in the intermittent group and 30 mg/kg/day the 
most common in the continuous group. Duration of treatment ranged from approximately 
1-2 weeks in many of the studies. Patients were predominately male and, when reported, 
were commonly exposed to different nephrotoxic medications.  
5.3.2 Risk of Bias 
A complete table with the risk of bias assessments is included in Table 5.2. The 
randomized clinical trials both had at least two areas at high risk of bias,54,55 notably with 
regard to blinding of participants/personnel and incomplete outcome data. Six of the 
observational studies were classified as low risk of bias (scored of 7-9), 3 studies as high 
risk of bias (score of 4-6), and none as very high risk of bias (score of 0-3).71,112-120 A 
funnel plot (Figure 5.2) suggests minimal publication bias. This was confirmed with the 
Harbord test (p=0.66).111 
5.3.3 Acute Kidney Injury 
The incidence and OR for study outcomes are displayed in Table 5.3. The pooled OR 
suggests an association between continuous infusion of vancomycin and a reduction in 






0.65) and is shown in Figure 5.3. Heterogeneity was fairly low with I2 of 15%. In 
sensitivity analysis, the observational studies (n=9) contribute heavily to the overall 
findings (OR 0.44; 95% CI 0.31-0.63) compared to the randomized controlled trials (n=2) 
(OR 0.72; 95% CI 0.30-1.73) (Figure 5.4). A sensitivity analysis was also performed to 
assess the risk of bias in contributing to the findings. For those studies deemed to be low 
risk of bias (randomized trials and those observational studies with a Newcastle-Ottawa 
score ≥ 7) (n=8), the OR for AKI with continuous infusion was less pronounced (OR 
0.52; 95% CI 0.33-0.82) in comparison to those studies deemed high risk of bias (n=3) 
(OR 0.37; 95% CI 0.22-0.61), but both analyses were statistically significant favoring 
continuous infusion to attenuate the risk of AKI (Figure 5.5). Additional sensitivity 
analysis assessing the impact of AKI/nephrotoxicity criteria comparing more sensitive 
definitions such as 50% increase in serum creatinine from baseline with more severe 
definitions such as need for renal replacement therapy yielded similar point estimates 
(Figure 5.6). In order to assess the impact of target trough concentrations in the 
intermittent arm and evaluate if higher troughs were possibly contributing to elevated 
area-under-the-curve (AUC) drug exposure, a sensitivity analysis was performed based 
on the target trough concentration: higher (15-20 mg/L) or lower (5-15 mg/L) (Figure 
5.7). Point estimates were again similar and statistically significant in both groups. 
Finally, in order to assess the impact of time and practice changes in regard to 
vancomycin dosing targets, a cumulative meta-analysis was conducted (Figure 5.8). As 
the pooled estimate was updated with each additional study, particularly during the time 
period 2001-2013, the beneficial effects of continuous infusion evolved and stabilized at 







Eight of the 11 included studies evaluated mortality, either as ICU or overall hospital 
mortality. There was no association between the infusion strategy of vancomycin and 
mortality in critically ill patients (OR 1.04; 95% CI 0.80-1.35) (Figure 5.9). Low 
heterogeneity was present (I2 0%).  
5.3.5 Pharmacokinetic Target Attainment 
Five of the included studies assessed in a dichotomous fashion the frequency with which 
the infusion strategy resulted in the goal pharmacokinetic target attainment for the 
protocol. These targets were a given concentration range for troughs for intermittent 
infusion and a single level range for continuous infusions. As compared to intermittent 
infusion, continuous infusion was associated with a 2.63 greater odds of pharmacokinetic 
target attainment (OR 2.63; 95% CI 1.52-4.57) (Figure 5.10). Moderate heterogeneity 
was present (I2 45%).  
5.4 Discussion  
This study represents the most focused systematic review and meta-analysis investigating 
the risk of AKI when comparing continuous with intermittent infusion of vancomycin in 
critically ill adults. The pooled estimates indicate the use of continuous infusion as 
compared to intermittent infusion of vancomycin is associated with an approximate 50% 
reduction in the odds of AKI. Given the ubiquity of vancomycin use in critically ill 
patients and the substantial morbidity and costs associated with AKI, the method of 
administration may have important effects on the drug safety profile without altering 
efficacy. Indeed, we found no difference in our secondary outcome of mortality between 






 Our study has many strengths, including the robust search strategy and focused 
patient selection that allowed us to examine the effects of infusion strategy in critically ill 
adults. Additionally, our meta-analytic techniques allowed us to pool adjusted Ors rather 
than raw, unadjusted numbers from prior reports. This is the most likely explanation why 
our study suggested a beneficial effect of continuous infusion vancomycin while a prior 
meta-analysis did not, as this method of data extraction and analysis is particularly 
important for a large cohort study under consideration that reported different effects on 
AKI in unadjusted and adjusted analysis.57,71 
 As recently demonstrated in an animal model, the AUC and maximum 
concentration (Cmax) of vancomycin during the dosing interval are most associated with 
injury biomarkers of AKI, specifically kidney injury molecule-1 (KIM-1).121 These data 
offer a potential mechanism to suggest a scientific rationale for the findings of our meta-
analysis: by avoiding high peak concentrations of vancomycin through delivery via a 
continuous infusion rather than intermittent dosing, the risk of vancomycin-associated 
AKI may be minimized. These markers of kidney injury were found in animals despite 
only 24 hours of exposure to vancomycin, thus the potential benefits of continuous 
infusion may be relevant to not only definitive MRSA therapy, but empiric therapy as 
well. In addition to the potential safety benefit, continuous infusion of vancomycin may 
be advantageous compared to intermittent infusion for other reasons. We found 
continuous infusion was associated with much greater pharmacokinetic target attainment 
(as dictated by the study’s dosing protocol) when compared to intermittent infusion. 
Given the anticipated guideline change to recommend AUC (as opposed to trough) 






monitoring costs may be minimized with continuous infusion (1 level required for 
evaluation) compared to intermittent infusion (2 levels required for evaluation). 
Additionally, dosing adjustments require far fewer assumptions and calculations and are 
vastly simplified with the continuous infusion approach. Continuous infusion may offer 
superior AUC/MIC target attainment over the dosing interval with less variability and 
thus optimize the delivery of vancomycin.122 Practically, a loading dose of 15-25 mg/kg 
is often recommended, followed by the maintenance dose infused over 24 hours. 
Following infusion of the drug for 24-48 hours and assuming relatively stable renal 
function, a level can be drawn and multiplied by 24 to obtain the AUC exposure.  
 Despite these possible advantages, certain barriers may limit the adoption of 
continuous infusion of vancomycin in all critical care settings. In an experiment 
involving human umbilical vein endothelial cells, vancomycin given continuously was 
noted to cause more endothelial cell toxicity compared to intermittent infusion.123 The 
Infusion Nurses Society identifies vancomycin as an intermediate-risk vesicant based on 
conflicting data.124 Given this, some institutions will choose to limit continuous infusion 
to central line administration only while others have successfully reported peripheral 
administration at concentrations of 6 mg/mL or less.113 Drug compatibility issues may 
also arise depending on availability of intravenous access when continuously infusing 
vancomycin.  
 This systematic review and meta-analysis is not without limitations. First, the 
majority of studies included in this systematic review and meta-analysis are 
observational, which limits their validity in comparison to prospective randomized trials. 






size (n=174 combined). However, the sensitivity analysis including only low risk of bias 
studies revealed a similar point estimate to the primary analysis, suggesting that while the 
data may be observational in nature, high risk of bias observational studies are not 
driving the primary findings. Similarly, many important infectious diseases clinical issues 
in critical care related to Staphylococcal infections have limited, or no, randomized 
controlled trial data to guide clinician decision making, including: AUC versus trough 
based dosing for vancomycin,23 nephrotoxicity risk of combination vancomycin and 
piperacillin-tazobactam,125 cefazolin versus nafcillin for methicillin-susceptible 
Staphylococcus aureus infections,126 and combination therapy for MRSA bacteremia.127 
Second, one emerging observation is AUC-based dosing of vancomycin is associated 
with reduced AKI compared to trough-based dosing, particularly given growing evidence 
that trough values correlate poorly with AUC and troughs of 15-20 mcg/mL may provide 
supratherapeutic exposure when assessed by the AUC.36,128 The possibility cannot be 
ruled out that continuous infusion is associated with less AKI in our analysis because 
continuous infusion regimens in these studies perhaps better controlled AUC within a 
therapeutic range without predisposing to elevations in AUC (despite trough 
concentrations at goal). However, the sensitivity analysis in the cohort targeting lower 
trough concentrations in the intermittent groups still found a statistically significant 
difference favoring a continuous infusion. Third, the AKI definition was not universal 
among all included studies and most were based on serum creatinine as the primary 
classification. However, the sensitivity analysis including studies with a definition of 
50% serum creatinine increase from baseline or 0.3-0.5 mg/dL increase from baseline 






Outcomes (KDIGO) stage 1 serum creatinine criteria for AKI,79 and the point estimate in 
Figure 5.6 mirrors that of the primary analysis. Finally, variations in the empiric dosing 
protocol and adjustment strategies introduce additional heterogeneity among studies. For 
example, more frequent loading doses in the continuous infusion group may have 
contributed to the association with greater percentage of pharmacokinetic target 
attainment (as defined by the dosing protocol used) with the continuous infusion 
strategy.129 It is also important to note that pharmacokinetic attainment was not the 
primary outcome of our systematic review and meta-analysis, thus other studies may 
exist that studied pharmacokinetic target attainment in critically ill patients, but did not 
include the primary outcome of AKI, that were excluded from our analysis.    
 Future studies should consider urinary biomarkers of tubular damage, such as 
KIM-1, as a mechanistic outcome comparing the two dosing strategies. Given that 
critically ill patients face many other potential insults to the kidney, controlling for 
severity of illness, use of vasopressors, concurrent nephrotoxins, relevant past medical 
history, and other factors should be carefully considered. AUC monitoring should be used 
as the dosing target as opposed to a single level or trough evaluation, with a goal of 400-
600 mg*hr/L.23 A standardized definition and grading of AKI as proposed by KDIGO 
should be employed,79 potentially with additional risk stratification as assessed by urinary 
biomarkers of tubular injury and dysfunction.130  
5.5 Conclusions 
In a meta-analysis of critically ill adults receiving vancomycin, continuous infusion was 
associated with a 53% reduction in the odds of AKI compared to intermittent infusion. 






infusion, may be contributing to sub-clinical and clinical AKI, additional prospective 
trials of continuous vs. intermittent infusion of vancomycin with AUC-targeted dosing 


























Table 5.1 Study Demographics  
Reference Study Design ICU Type Infection 
Definition of Acute 
Kidney 
Injury/Nephrotoxicity 
Target (mg/L) Loading Dose Dosing Regimen 
CI II CI II CI II 




≥0.5 mg/dL or ≥50% 
increase in SCr 20-25 
Ctr=15-









SCr increase 1.5 times 
baseline or absolute 
increase in SCr ≥ 0.3 
mg/dL 









SCr increase of ≥ 0.3 
mg/dL or 1.5 to 2 times 
increase from baseline 
on at least 2 consecutive 
days and/or urine output 
< 0.5 mL/kg/hr for >6 
hours 













SCr increase ≥ 50%; 
eGFR decrease ≥ 25%; 
SCr ≥ 3.95 mg/dL 
NR NR NR NR NR NR 
Hong 2015 Cohort (retrospective) Neurosurgical 
Pathogen: 
16% S. aureus 
Source: Multiple 
≥ 50% increase in SCr; 
SCr > 0.5 mg/dL from 
baseline; ≥50% 
decrease in CrCl on at 
least 2 consecutive days 




















≥50% increase in SCr in 
48 hours; ≥0.3 mg/dL 
rise in SCr in 48 hours; 
<0.5 mL/kg/hr urine 
output > 6 hours 




(retrospective) Medical ICU Unspecified 
Need for renal 






















SCr increase ≥ 50% 
from baseline 15-25 
Ctr: 15-















RIFLE criteria for 









500 mg q6h 











Rise in SCr of 0.5 
mg/dL or more if initial 
level <3 mg/dL 
Rise of 1 mg/dL or 




















50% increase in SCr 
from day treatment was 
started to end of 
treatment 















Table 5.1 (continued) 
Reference 
Regime















CI II CI II CI II CI II CI II CI II CI II CI II 






























































930 7 (7-8) 
7 (7-
10) 86 100 
Hanrahan 
2014  46  28





































































































0.21 NR NR NR NR NR
e NRe 
Tafelski 













8) NR NR 
Wysocki  
















13 NR NR 
Wysocki 




16 73 ± 15 69 ± 17 69 60 














13 ± 5 14 ± 6 59 74 
ICU = intensive care unit; CI = continuous infusion; II= intermittent infusion; MRSA = Methicillin-resistant Staphylococcus aureus;  
SCr = serum creatinine; Cpk = peak concentration; Ctr = trough concentration; NR =  not reported 
aMeans reported as means ± standard deviation and medians as median (interquartile range) 
bReported only for GPC bacteremia cohort 
cNot add up to 100 due to classification of a mixed category as well 
dIncluded vasopressors  











Table 5.2 Risk of Bias Assessment  
Study 
 Randomized Clinical Trials 






















Other Bias   
Schmelzer 
2013 
Low Unclear High Low High High High   
Wysocki 
2001 
Low Low High Low High Unclear Low   
























y of cohorts 
on the basis 














Akers 2012 * * * 0 0 * * * 6 
Bissell 2018 * * * 0 0 * * * 6 
Duszynska 
2016 
* * * 0 ** * * * 8 
Hanrahan 
2014 
* * * 0 ** * * 0 7 
Hong 2015 * * * 0 ** * * * 8 
Hutschala 
2009 
* * * * ** * * * 9 
Saugel 2013 * * * 0 0 * * 0 5 
Tafelski 2015 * * * 0 * * * * 7 
Wysocki 
1995 















Table 5.3 Study Outcomes 
Reference Acute Kidney Injury/ Nephrotoxicity 
 Mortality Pharmacokinetic Target 
Attainment % 
 CI II OR
a CI II OR
































































































(0.10-0.73) NR NR 























































































































Figure 5.4 Sensitivity Analysis: Impact of Study Design on Outcome of AKI 
 
Randomized Controlled Trials (n=2) 
 
















Figure 5.5 Sensitivity Analysis: Impact of Risk of Bias on Outcome of AKI 
 
Low Risk of Bias (n=8) 
 
















Figure 5.6 Sensitivity Analysis: Impact of AKI/Nephrotoxicity Criteria on Outcome of 
AKI 
 
Less Severe Definition: 50% Serum Creatinine Increase From Baseline or 0.3-0.5 mg/dL 
Increase From Baseline (n=9) 
 
 













Figure 5.7 Sensitivity Analysis: Assessment of Vancomycin Trough Target on Outcome 
of AKI 
 
Intermittent Trough Target: 15-20 mg/L (n=6) 
 
 













































































































In a recent survey of critical care practitioners, continuous infusion vancomycin 
was identified as rarely used by 94.2% of respondents.75 Continuous infusion 
vancomycin offers many advantages to intermittent infusion, including fewer 
concentration assessments and less complex mathematical calculations for AUC 
monitoring,131 greater consistency in steady state concentrations,132 and importantly, 
potentially less acute kidney injury.70 A number of population pharmacokinetic models 
have been developed for vancomycin administered via intermittent infusion in critically 
ill patients.133 However, likely given the low reported frequency of use, less 
pharmacokinetic modeling has been performed on continuous infusions of vancomycin in 
this patient population.134 In our recent meta-analysis of continuous versus intermittent 
infusion of vancomycin in critically ill adults,70 we noticed that while intermittent 
infusions of vancomycin are typically dosed via nomogram, it was less common to 
personalize dosing for continuous infusion and a dose of 30 mg/kg/day was most 
commonly used. When comparing these two infusion strategies head-to-head, it seems 
necessary that we would compare precise dosing of intermittent infusion with precision 
dosing of continuous infusions. Accordingly, we sought to develop a population 
pharmacokinetic model of continuous infusion vancomycin in critically ill adults.  
6.2 Methods 
6.2.1 Study Design 
This was a prospective, observational study of continuous infusion vancomycin in 
a medical intensive care unit (ICU) of a tertiary care, academic referral center from June 






Kentucky is established by a Pharmacy and Therapeutics committee approved protocol 
that authorizes pharmacists to adjust doses and order vancomycin concentrations. As part 
of our institutional shift from trough to AUC-based monitoring,94 continuous infusion 
vancomycin was instituted in the protocol for consideration in critically ill patients, 
patients requiring >4,000 mg vancomycin per day, or those unable to obtain therapeutic 
AUC on intermittent infusions. The decision to use continuous or intermittent infusion at 
this time was based on the discretion of the pharmacist dosing and monitoring 
vancomycin. Continuous infusion was only advised for use with patients deemed to have 
stable renal function, and a loading dose of vancomycin 25 mg/kg was recommended if 
employing a continuous infusion. Administration via a central line was recommended if 
available, but based on other data using < 6 mg/ml concentrations, peripheral 
administration was allowed.113 Adult patients were prospectively identified during this 
time period, and included if they received a continuous infusion of vancomycin and had 
serum vancomycin concentrations drawn during routine clinical care. Patients requiring 
continuous renal replacement therapy were excluded. The study was approved by the 
Institutional Review Board at the University of Kentucky with a waiver of informed 
consent (#56908).  
6.2.2 Data Collection 
 Data were collected as documented in the electronic medical record. All doses, 
time stamps, and vancomycin serum concentrations were extracted to build the model 
data file. Covariates collected for evaluation in the pharmacokinetic model included: age, 
race, sex, height, weight, Sequential Organ Failure Assessment score, serum creatinine, 






Corcoran96), serum blood urea nitrogen (BUN), serum sodium, serum chloride, serum 
phosphorous, serum albumin, presence of cirrhosis, norepinephrine equivalents, and 
cumulative fluid balance in hospital stay.  
6.2.3 Laboratory Analysis 
Serum vancomycin samples were analyzed in the hospital’s clinical laboratory using a 
Roche Cobas kinetic interaction of microparticles in a solution (KIMS)-based 
immunoassay (Roche Diagnostics Corporation, Indianapolis, IN). All other laboratory 
parameters were obtained from documentation during routine clinical care.  
6.2.4 Pharmacokinetic Modeling 
Pharmacokinetic modeling was performed in Monolix using non-linear mixed effects 
modeling with the Stochastic Approximation Expectation-Maximization (SAEM) 
algorithim.135,136 Complete data were present for all doses and concentrations assessed. 
Covariate values present at the time of initial vancomycin dose were used for covariate 
modeling in Monolix.  
6.2.5 Structural Model  
The structural model for the data was determined by testing one- and two-compartment 
models, with elimination rate constant or clearance models, and with linear or Michaelis-
Menten elimination assuming lognormal distributions of parameters with random effects. 
Parameter estimation is based on minimizing the objective function value (OFV) using 
maximum likelihood estimation.60,137 Because more complex models with additional 
parameters offer more degrees of freedom for the model to take different shapes and 
therefore better able to describe the data, it is necessary to account for the additional 






Bayesian information criterion (BIC) with the following where OBJ is the minimum 
OFV, ηp is the number of parameters in the model, and N is the number of data 
observations.60  
AIC = OBJ + 2 ⸱ ηp 
BIC = OBJ + ηp ⸱ Ln(N) 
Since BIC penalizes for greater model complexity, and therefore may be preferable when 
data are limited, we primarily used BIC for comparing structural models in addition to 
visual review of observed vs. predicted plots, scatter plot of residuals, and individual 
subject model fits.60 We used the classification of Kass and Raftery to assess model 
differences in BIC, with differences of >10 deemed “very strong” evidence in factor of 
the model with the lower BIC.60,138  
6.2.6 Covariate Selection  
The relationship between covariates and the parameter estimates was assessed with 
Pearson’s correlation tests or analysis of variance (ANOVA) for continuous and 
categorical variables, respectively. Using power law relationships, continuous covariates 
were log-transformed using the following formula: log (covariate divided by the 
weighted mean of the dataset). Clearance and volume were allometrically scaled for 
weight using fixed coefficients of 0.75 and 1, respectively.139,140 Covariate selection was 
further informed by the COnditional Sampling use for Stepwise Approach based on 
Correlation tests (COSSAC) algorithm in Monolix.135 
6.2.7 Error Model 
Once the covariates for inclusion were identified, the residual error model was developed 






constant, proportional, or combined error model.135,141 Reiterations of the model were 
performed until the optimized model was found as assessed using BICc.  
6.2.8 Final Model 
The final model was selected based on the change in OBJ, with a reduction of 3.84 
considered statistically significant (p<0.05, chi squared distribution, degree of freedom 
=1), lowest AIC and BIC scores, goodness-of-fit checks including individual patient 
review of observed vs. predicted, between subject variability associated with population 
estimates, and the rule of parsimony.   
6.2.9 Simulations 
Using population estimates from the final population pharmacokinetic model, Monte-
Carlo simulations were performed in Simulx142 assessing AUC target attainment of 400-
600 mg⸱hr/L for three discrete time intervals: AUC0-24, AUC24-48, and AUC48-72. These 
time intervals were selected given the importance of early AUC target attainment within 
initial days of therapy, but also since empiric therapy in the ICU setting is often 48-72 
hours in duration. Given vancomycin is typically dosed on a mg/kg basis clinically, and 
extremes of weight may lead to issues of dose capping, we simulated individuals of more 
typical weights of 70-100 kg. Drawing from a similar distribution of age (mean 55 ± 16) 
and BUN (23.1 ± 16.6 mg/dl) as our population, we first simulated 1000 patients with the 
typical recommendation of a 25 mg/kg loading dose and 30 mg/kg/day maintenance dose 
to begin immediately following the completion of the loading dose. The initiation timing 
of the maintenance dose in relation to the loading dose was examined to determine the 
impact of delaying the start of the maintenance dose on AUC target attainment. Using 






develop a simplified dosing nomogram for continuous infusion vancomycin considering 
these covariates. This process was iteratively repeated in 5 mg/kg/day intervals for the 
loading and maintenance doses, seeking the combination that maximized AUC target 
attainment within 72 hours while attempting to limit the frequency of supratherapeutic 
AUCs at any given time point to <25% if possible.  
6.3 Results 
As noted in the inclusion criteria, all patients were critically ill and admitted to the 
medical ICU. Patient demographics are shown in Table 6.1. The data consist of 239 
dosing events and 124 vancomycin concentrations from 50 critically ill patients. Nine 
patients had two serum concentrations assessed following the loading dose, while an 
additional eight patients had a single serum concentration assessed following the loading 
dose, prior to any subsequent dosing.  
6.3.1 Structural Model 
 All structural models assessed are shown in Table 6.2. The structural model 
selected was a one (1) compartment model using the parameters volume (V) and 
clearance (CL). As seen in Table 6.2, we considered the difference in BIC of >10 
between this and the next closet model very strong evidence in favor of this model as 
described in our methods.60,138  Visual inspection revealed acceptable observed vs. 
predicted concentrations, individual fits of the model to concentrations from each subject, 
appropriate distribution of the residuals, and acceptable relative standard errors (RSEs) of 






6.3.2 Covariate Selection 
Figure 6.1 shows correlations between covariates and the parameter estimates for V and 
CL. Statistical comparisons are shown in Table 6.3. In addition to allometrically scaled 
weight using fixed values of 0.75 and 1 for clearance and volume, respectively, 
covariates retained in the final model included serum BUN and age with significant 
effects on clearance.   
6.3.3 Error Model 
The best residual error model identified was the proportional error model shown below, 
where Cc is the predicted concentration, b represents the error model parameter, and e is 
a standard normal random variable that generates the residual error.141  
Observation = Cc + b*Cc * e  
6.3.4 Final Model 
Given significant between subject variability for volume when modeled as a random 
effect, volume was modeled as a fixed effect in the final model using the allometrically 
scaled weight. The final model is shown below, where ηCl is the random effect of 
clearance.  
log(V) = log (Vpop) + βV_logWT*logWT 
log(CL) = log(CLpop) + βCl_logAGE * logAGE + βCl_logBUN* logBUN + βCl_logWT *logWT + 
ηCL  
The final population parameter estimates for the model are shown in Table 6.4. The 
observed vs. predicted concentrations are shown in Figure 6.2 for the population 






outlier proportion=5.65%). The residuals are appropriately distributed as shown in 
Figures 6.3 and 6.4. The distribution of CL is shown in Figure 6.5 (shrinkage -7.63%). 
Distribution of the CL standardized random effect is shown in Figure 6.6 and is 
appropriately centered around zero. Assessment of model convergence was appropriate 
(Figure 6.7).  
6.3.5 Simulations 
Using population parameters and the final population pharmacokinetic model and 
simulating 1000 patients weighing between 70-100 kg with the traditional 
recommendation of a 25 mg/kg loading dose followed by 30 mg/kg/day continuous 
infusion, we observed a high frequency of supratherapeutic AUC0-24, AUC24-48, and 
AUC48-72 values (Table 6.5). This is shown graphically in Figure 6.8, where the median 
concentration of the continuous infusion is just under 30 mg/L, while a continuous 
infusion steady state concentration of 17-25 mg/L (multiplied by 24) corresponds to AUC 
values within 400-600 mg⸱hr/L. We observed that extending the time from the start of the 
loading dose to initiation of the continuous infusion maintenance dose allowed for 
optimization of AUC across the time periods evaluated, particularly avoiding 
supratherapeutic AUC0-24 (Table 6.5). Using the iterative process described to maximize 
AUC target attainment while attempting to keep the frequency of supratherapeutic AUC 
exposure to <25% at each time period, if possible, we determined that the optimal 
regimen of vancomycin continuous infusion for a typical individual weighing 70-100kg 
was a 20 mg/kg loading dose (dosed on actual body weight) followed by a continuous 
infusion of 20 mg/kg/day to begin 12 hours following the initiation of the loading dose. 






population used for model development, this regimen achieved AUC target attainment at 
24, 48, and 72 hours 58.4%, 40.7%, and 37.9% of the time, respectively, while 
minimizing the frequency of supratherapeutic AUC exposure to under 25%. The 
simulated concentration versus time profile and AUC0-24, AUC24-48, and AUC48-72 for this 
regimen are shown in Figures 6.9 and 6.10, respectively.   
 Given that serum BUN, age, and weight were identified as significant covariates, 
we attempted to develop a simplified dosing nomogram using these covariates. Based on 
our simulations, we designed the maintenance dose of continuous infusion to begin 12 
hours following the start of the loading dose. Age and BUN were categorized as above or 
below their mean values from the covariate distribution and simulated in the following 
categories: age (18-55), age (56-80), BUN (≤ 23 mg/dl) and BUN (24-75 mg/dl). The 
two-by-two nomogram created that maximized AUC target attainment and attempted to 
limit supratherapeutic AUC frequency to <25% is shown in Table 6.6. Given that we 
modeled volume as a fixed rather than random effect, we kept the 20 mg/kg loading dose 
constant in the proposed nomogram. This simplified nomogram demonstrates improved 
simulated AUC0-24, AUC24-48, and AUC48-72 target attainment compared to the universal 
20mg/kg loading, 20 mg/kg/day maintenance regimen derived in Table 6.5.  
6.4 Discussion 
 Using data from 50 patients in a medical ICU receiving continuous infusion 
vancomycin, we were able to fit a population model to the data that reasonably explained 
the vancomycin concentrations observed. A one-compartment model with clearance and 






 In 2011, Roberts and colleagues published a population pharmacokinetic model of 
continuous infusion vancomycin.143 Similar to our model, the final model was a one-
compartment model with clearance and volume. Total body weight was a significant 
parameter in describing volume of distribution and urinary creatinine clearance best 
described vancomycin clearance. Compared to our model, their estimate of population 
clearance was slightly higher (mean 4.58 L/hr). While the R2 of our observed vs. 
individual predicted concentrations was similar at 0.60 in each study, our observed 
population vs. predicted concentrations was improved (R2=0.26 vs. 0.07), suggesting our 
model may perform superior for empiric dosing of vancomycin in this population.143 The 
exact type of ICU patient in the model (surgical vs. medical) developed by Roberts et 
al143 is unclear, but may explain their higher clearance. For example, trauma and 
neurocritically ill patients may be at a higher likelihood of augmented renal clearance and 
have additional comorbidities impacting vancomycin clearance compared to a medically 
critically ill patient population such as ours. A similar one-compartment model was 
developed in 2017 parameterized by clearance and volume.144  Creatinine clearance was 
included as a covariate influencing vancomycin clearance and total body weight as a 
covariate impacting volume. Additionally, mechanical ventilation, tested for its potential 
biologic rationale of lowering cardiac output and renal blood flow, was included with a 
significant covariate effect on vancomycin clearance.144  
 Several other comparisons between these prior models and our model deserve 
discussion. First, although components of typical creatinine clearance equations including 
age and weight were included in our model, creatinine clearance was not a significant 






discussed.143,144 Models can only describe the data they are developed from, and patients 
in our cohort likely represent a population deemed to have relatively stable renal function 
for the pharmacist dosing to use continuous rather than intermittent infusions, which is 
supported by the baseline serum creatinine and BUN from Table 6.1. From this cohort 
however, we did observe BUN as the strongest covariate effect on vancomycin clearance. 
BUN was not evaluated in the prior models developed.143,144 BUN is often concomitantly 
measured with serum creatinine as a measure of renal function; approximately 85% of the 
body’s urea is eliminated by the kidney.145 Just as serum creatinine is identified as a 
relatively insensitive marker to loss of renal function, several factors in critical care can 
influence BUN including protein intake and liver disease to name a few.145 Even though 
BUN is a recognized poor marker of GFR, its elevation is associated with mortality in 
several disease states and may reflect on tubular function of the kidneys to some extent as 
well, which is also known to influence vancomycin secretion.146,147 Second, unlike other 
models that modeled volume as a random effect, the between subject variability in 
volume led us to model volume as a fixed effect. Despite our efforts to capture potential 
measurable covariate influencers of this parameter, including cumulative fluid balance, 
we were unable to account for the variability of this parameter, which is known to exhibit 
significant variability in critically ill patients, with both inter-and intra-patient variability 
depending on clinical status.148  
 Our simulations performed using this model provide additional insights into 
optimal continuous infusion vancomycin dosing. Although it is recognized that a loading 
dose of vancomycin is advisable when using continuous infusions due to the potential 






combination and relative timing of loading and maintenance initiation are not abundantly 
clear based on published literature. Updated vancomycin consensus guidelines 
recommend a loading dose of 20-35 mg/kg vancomycin (up to 3,000mg) if considering 
intermittent dosing, although at the time of vancomycin initiation it may be unclear 
whether intermittent or continuous infusion regimen will be pursued, particularly if 
started in the emergency department for example where the patient is originally 
assessed.23 If using continuous infusion vancomycin, consensus recommendations 
suggest consideration of a loading dose of 15-20 mg/kg and a maintenance dose of 30-40 
mg/kg/day.23 Our findings agree with a component of this recommendation, in that we 
found greater AUC target attainment over 72 hours, with reduced frequency of 
supratherapeutic AUC with a lower loading dose of 20 mg/kg. Additionally, our 
simulations suggested that delaying the initiation of the maintenance dose to 12 hours 
following the start of the loading dose also maximized AUC target attainment while 
minimizing supratherapeutic AUC0-24 that may have been due to administration of the 
maintenance dose beginning immediately following the loading dose. This is highly 
clinically relevant and suggests that the decision to initiate maintenance dosing for 
continuous infusion can be delayed for 12 hours while other important elements occur, 
including any transitions of care and further evaluation of intravenous access, which may 
be a critical consideration to use continuous vancomycin or not. Contrary to the model by 
Roberts143 and consensus guideline recommendations,23 our simulations suggest 
significantly lower maintenance doses of vancomycin in medically critically ill 
individuals. While we determined a maintenance dose of 20 mg/kg/day optimized the 






average, we saw much greater success with the simplified nomogram we developed using 
weight-based dosing with the covariates of serum BUN and age that we derived from our 
model. In a previous study involving a similar medically critically ill population, we 
found AUC target attainment to only be 32.4% with empiric intermittent infusion dosing, 
which was increased to 58.6% with the use of first-dose pharmacokinetics.149 Our 
proposed nomogram, if validated, would provide potentially even greater precision and 
accuracy, with far fewer labor and laboratory costs, to optimize AUC target attainment 
over the initial days of therapy.   
 Our study has several strengths, including the vancomycin concentration-to-
patient ratio of almost 3:1 and large number of biologically relevant covariates 
investigated for a drug known to exhibit substantial inter-patient variability. Our final 
population pharmacokinetic model was able to well-describe the observed versus 
individual predicted serum vancomycin concentrations. We simulated clinically relevant 
scenarios to help inform optimal dosing of continuous infusions and were able to derive a 
simplified nomogram that could assist with empiric vancomycin dosing when given via 
continuous infusions. Several limitations deserve mention as well. First, these are data 
from a single ICU at a single center and a relatively small number of patients. Second, 
this model, including our proposed nomogram, has not been externally validated. While 
the model and covariates deserve additional study for validation, the covariates in our 
model are static on the day of vancomycin initiation and changes during critical illness 
may influence the impact of these covariates have on the final model. More sophisticated 







We developed a population pharmacokinetic model of continuous infusion 
vancomycin in critically ill adults which adequately described the data using a one-
compartment model with volume and clearance, and covariates of serum BUN, age, and 
weight. A simplified dosing nomogram optimized AUC target attainment over the initial 
72 hours of therapy using these covariates. Future research to validate this model can 
help to inform precision dosing of continuous infusions of vancomycin in critically ill 
patients.  




















Table 6.1 Patient Demographics at Time of First Vancomycin Dose 
Patient Characteristic (n=50) Descriptive Statisticsa   
Age (years) 59 (46.5-68) 
Race (% white) 46 (92%) 
Sex (% male) 27 (54%) 
Height (cm) 167.6 (162.9-177.8) 
Weight (kg) 90.7 (64.2-109.1) 
Sequential Organ Failure Assessment score 6 (5-9) 
Serum creatinine (mg/dl) 0.8 (0.6-1.0) 
Serum blood urea nitrogen (mg/dl) 20 (13-27) 
Serum sodium (mmol/l) 140 (137-142) 
Serum chloride (mmol/l) 104 (100-107) 
Serum albumin (g/dl) 2.5 (2.0-2.9) 
Serum phosphorus (mg/dl) 2.7 (2.2-3.4) 
Cirrhosis (%) 8 (16%) 
Norepinephrine equivalents (mcg/kg/min) 0 (0-0.03) 
Net fluid balance (ml) -102 (-906 to 798) 
Initial vancomycin dose (mg) 2000 (1500-2500) 
Initial vancomycin dose (mg/kg actual body 
weight) 
22 (17-24) 


















Table 6.2 Evaluation of Structural Model 
Run Compartment Elimination Parameters OFV AIC BIC BICc 
01 1 Linear V, k 829.8 841.8 853.3 856.9 
02 1 Linear V, Cl 815.6 827.6 839.1 842.7 
03 1 MM V, Km, Vm 826.7 842.7 858.0 862.6 
04 2 Linear V1, Q, V2, Cl 813.5 833.5 852.6 858.1 
05 2 Linear V, k1,2, k2,1, k 814.0 834.0 853.1 858.6 
06 2 MM V1, Q, V2, 
Km, Vm 
812.7 836.7 859.6 866.0 
07 2 MM V, k1,2, k2,1, 
Km, Vm 
822.1 846.1 869.0 875.4 
OFV= -2 x log-likelihood; AIC= Akaike Information Criteria; BIC= Bayesian Information Criteria; BICc= 
Corrected Bayesian Information Criteria; k=elimination rate constant; V= volume of distribution; Cl= 
Clearance; MM=Michaelis-Menten; Km= Michaelis constant; Vm=maximum rate; V1= central 
compartment; V2=peripheral compartment; Q=intercompartmental clearance; k1,2=rate of transfer from 




















Table 6.3 Statistical Evaluation of Covariates with Random Effects  
 
V 
 COEFF STATISTICS P-VALUE 
LIVER  0.058 8.1e-1 
RACE  0.76 4.73e-1 
SEX  0.92 3.42e-1 
AGE 0.023 0.16 8.75e-1 
ALBUMIN -0.0025 -0.018 9.86e-1 
BUN -0.2 -1.43 1.59e-1 
CHLORIDE -0.04 -0.28 7.82e-1 
CRCL 0.16 1.13 2.66e-1 
FLUID BALANCE 0.0064 0.044 9.65e-1 
HT 0.052 0.36 7.21e-1 
SODIUM -0.2 -1.43 1.6e-1 
PHOS -0.2 -1.4 1.68e-1 
SCR -0.15 -1.02 3.15e-1 
SOFA -0.16 -1.09 2.79e-1 
VASOPRESSORS 0.022 0.15 8.8e-1 










Table 6.3 (con) 
CL 
 COEFF STATISTICS P-VALUE 
LIVER  0.15 7.03e-1 
RACE  0.046 9.55e-1 
SEX  2.29 1.36e-1 
AGE -0.26 -1.89 6.43e-2 
ALBUMIN -0.015 -0.1 9.2e-1 
BUN -0.45 -3.48 1.08e-3 
CHLORIDE -0.12 -0.83 4.12e-1 
CRCL 0.35 2.61 1.21e-2 
FLUID BALANCE 0.17 1.2 2.35e-1 
HT 0.24 1.75 8.71e-2 
SODIUM -0.18 -1.25 2.16e-1 
PHOS -0.28 -1.99 5.22e-2 
SCR -0.15 -1.05 2.99e-1 
SOFA -0.085 -0.59 5.55e-1 
VASOPRESSORS -0.14 -0.95 3.45e-1 









Table 6.4 Population Pharmacokinetic Parameter Estimates  
 Value Standard error Relative standard error 
(%) 
Fixed Effects 
Vpop  44.37 3.46 7.81 
βV_logWT 1   
Clpop 4.18 0.2 4.74 
βCl_logAGE -0.35 0.13 38.3 
βCl_logBUN -0.3 0.074 25.2 
βCl_logWT 0.75   
Standard Deviation of the Random Effects 
ωCl 0.28 0.037 13.5 
Error Model Parameters 















Table 6.5 Area-Under-the-Curve Target Attainment for Tested Loading and Maintenance 
Dose Combinations Using Monte-Carlo Simulations 
Loading Dose Maintenance Dose AUC0-24 AUC24-48 AUC48-72 
Loading Dose Over 2.5 Hours Immediately Followed by Initiation of Continuous 
Infusion 













































Loading Dose Over 2.5 Hours with Continuous Infusion Commencing 12 Hours 
Following Start of Loading Dose 







Sub: 16.8%  
Supra: 41.9% 






























Table 6.6 Proposed Dosing Nomogram and AUC Target Attainment 
Category Age ≤ 55 Age >55 
BUN 
>23 
Load: 20 mg/kg 
Maintenance: 20 mg/kg/day  
 
Load: 20 mg/kg 
Maintenance: 15 mg/kg/day 
 
























Load: 20 mg/kg 
Maintenance: 30 mg/kg/day 
 
Load: 20 mg/kg 
Maintenance: 25 mg/kg/day 
 






















Simulation for patient weights 70-100 kg with maintenance dose beginning 12 hours following initiation of the loading dose.  





























































































































































































Figure 6.8 Simulation of 1000 Patients of Typical Weight (70-100kg): 25 mg/kg Loading 















Figure 6.9 Simulation of 1000 Patients of Typical Weight (70-100 kg): 20 mg/kg Loading 
Dose Followed by 20 mg/kg/day Continuous Infusion Starting 12 Hours Following Start 















Figure 6.10 Area-Under-the-Curve Simulation of 1000 Patients of Typical Weight (70-
100 kg): 20 mg/kg Loading Dose Followed by 20 mg/kg/day Continuous Infusion 



























































7.1 Aim 1  
Our series of studies further inform precision drug delivery of vancomycin to 
critically ill patients. We primarily were interested in evaluation of three techniques to 
optimize drug delivery of vancomycin to critically ill patients: loading doses, first-dose 
pharmacokinetic evaluation, and use of continuous rather than intermittent infusion. With 
these strategies in mind, we began our work in aim 1 by first establishing practice 
patterns of critical care clinicians related to vancomycin drug delivery.75 We found that 
two of the drug delivery techniques that we were interested in studying were infrequently 
used by practicing pharmacists in adult critical care units.75 Ninety four percent of our 
survey respondents either rarely or only sometimes reported first-dose pharmacokinetic 
evaluation to guide empiric dosing. Similarly, 98.6% of respondents reported rarely or 
only sometimes using continuous infusions of vancomycin.75 If we were to demonstrate 
improvements in precision drug delivery with these strategies, they could have the 
potential to change the way vancomycin is delivered to critically ill patients throughout 
the world based on our international survey showing a low prevalence of these practices. 
We hypothesized that the frequency of loading doses would be more common given their 
recommendation in vancomycin consensus guidelines,23 but still observed differential 
reported frequency across various scenarios.75 Anticipating this based on a previous study 
of vancomycin dosing practices,39 we sought to understand barriers for clinicians not 
reporting more frequent use of loading doses and incorporate these hesitations into our 
methods of aim 2. Indeed, a recent systematic review of implementation science research 
in emergency medicine emphasized the importance of understanding barriers and 






7.2 Aim 2  
These findings were important to us in designing our study assessing vancomycin 
loading doses in aim 2 and drove the inclusion of the primary outcome as clinical failure 
and ensuring assessment of the secondary outcome of acute kidney injury. Simply put, 
we sought to use this survey to ascertain clinician barriers to using loading doses, and 
then use those concerns to try and design a study to test if those concerns were valid. Our 
study in aim 2 of loading doses should alleviate concerns of nephrotoxicity from loading 
doses that some clinicians had in our survey, but also likely supports their non-universal 
use of a loading dose based on the lack of impact of observed clinical outcomes.75 This 
highlights an important facet for further research in precision dosing of vancomycin, or 
any medication for that matter, in clinical care: while optimization of pharmacokinetic 
target attainment may be perceived to be beneficial by researchers and even guidelines, it 
may be insufficient to persuade clinicians to universally adopt, particularly if the action is 
accompanied by an increased workload, risks to the patient, or other disadvantages. 
Indeed, since the release of the revised vancomycin consensus guidelines recommending 
AUC over trough monitoring, this approach has been vigorously challenged in the 
literature, the outcomes justifying use of AUC over trough monitoring, and resources 
required to do so.151-154 Given the link of vancomycin-associated nephrotoxicity with real, 
adverse clinical outcomes, including hospital readmissions and mortality and the 
associated healthcare costs, the counter-debate is that vancomycin AUC monitoring 
reduces the risk of nephrotoxicity.155 Even with the recognition that vancomycin-induced 
nephrotoxicity most commonly occurs after 4-5 days of treatment,44 the consideration 






regarding the injury potentially present earlier in therapy, including sub-clinical kidney 
injury. Indeed, AUC monitoring may be cost-effective from the acute kidney injury 
perspective alone.156 Interestingly, since completion of aim 2, another group has 
evaluated the efficacy of vancomycin loading doses on critically ill patients with MRSA 
pneumonia.157 Although the sample size was smaller, they also observed no difference in 
any clinical efficacy outcomes.157 While we believe early AUC target attainment within 
the initial days of therapy to still be critical from a safety perspective if nothing else, and 
while our work does not provide definitive answers to this topic in the manner that a 
randomized controlled trial would, we find it unlikely that future research on clinical 
outcomes related to a single, initial dose of a drug in MRSA infection would yield 
significant, patient-centered differences in outcomes.  
7.3 Aim 3 
 As an early adopter of the transition to AUC-guided vancomycin dosing, our team 
had clinical experience with vancomycin AUC dosing. Our anecdotal experience was that 
traditional nomograms, or even clinical judgement used to guide empiric dosing of 
vancomycin, was producing wide-ranging AUCs, very few of which were in the target 
range. In aim 3, we confirmed this suspicion where we found that empiric dosing of 
vancomycin in critically ill medical ICU patients achieved AUC target attainment at 
steady state only 32.4% of the time.149 By using a first-dose pharmacokinetic approach in 
patients with stable renal function, whereby 2 vancomycin concentrations were assessed 
following the first dose to calculate patient-specific pharmacokinetic parameters, we 
demonstrated this approach nearly doubled AUC target attainment at steady state to 






dosing information assures more precise dosing and less likely to see variability in AUC. 
If the patient has confirmed MRSA, this is advantageous to ensure appropriate AUC/MIC 
attainment. If the therapy is empiric, this ensures the patient does not experience 
unnecessary and risky extremes of vancomycin exposures given vancomycin’s 
nephrotoxicity risk, particularly in critically ill patients with multiple kidney insults 
present at any given time. The challenge to precision dosing of any medication, including 
vancomycin, is that increasing precision will come with added cost of care. In the case of 
Bayesian software programs, the cost is more tangible, direct, and known up-front, which 
has been documented to hinder their use in practice.158 While this first-dose 
pharmacokinetic approach does not carry those same costs, it does come with costs of 
additional vancomycin concentrations and clinician effort to appropriately use the 
information gained from very early concentration assessment. We suspect that clinicians 
with a prior belief that early AUC target attainment is clinically relevant for efficacy and 
safety outcomes will be attracted by this approach, while skeptical clinicians with low 
prior beliefs about the value of early AUC target attainment are less likely to implement. 
Since even the Bayesian methods rely heavily on the population pharmacokinetic models 
incorporated and produce more accurate predictions once a patient’s own vancomycin 
concentration has been incorporated into the Bayesian forecasting,159,160 one possible 
expansion of this research in the future may include the assessment of a single 
vancomycin concentration following the initial dose to better inform precise dosing of 
vancomycin.   
 Using the first-order pharmacokinetic equations in clinical practice in the same 






doses are often not administered at the exact time intervals, concentrations are not always 
drawn at precise times, and other logistical issues. As our center instituted AUC 
monitoring and developed the protocol for first-order pharmacokinetic equations, one 
gains an appreciation of the sheer amount of inherent potential error in this math. 
Variability occurs in not only the measurement of the vancomycin concentration from the 
laboratory, but also assumptions about the occurrence of steady state, that levels are 
obtained one half-life apart, back- and forward- extrapolations for concentrations that are 
drawn late or early, respectively. Our interest in continuous infusions of vancomycin was 
based not only on the ease of clinical use and relaxing some of the assumptions and 
resources required to monitor (one concentration required for AUC assessment versus 
two), but also due to an interest that continuous infusions of vancomycin may reduce the 
risk of acute kidney injury.  
7.4 Aim 4 
 As we noted in aim 4, our meta-analysis was unique in that it focused on critically 
ill patients and used appropriate statistical techniques to account for the adjusted effect 
estimates produced from some of the included studies. For example, pooling results from 
critically ill patients and patients receiving home infusions of vancomycin is analogous to 
pooling apples and oranges, a common critique of meta-analytic approaches in general. 
The authors of prior cohort studies took care to adjust for confounding in their 
presentation of the results, and it seems appropriate that these adjusted estimates (i.e. with 
confounding minimized) would be appropriate to pool rather than unadjusted estimates 
from non-randomized studies. In the meta-analysis of aim 4, we found that continuous 






reduction in the odds of acute kidney injury.70 As we continue to plan for future studies 
comparing continuous versus intermittent infusion of vancomycin and kidney injury, this 
estimate can help us derive a planned effect size for sample size calculations.  
 Similar effects of continuous versus intermittent infusion have been observed in 
pre-clinical models as well. Supporting this concept of peak vancomycin concentrations 
being a driver of kidney injury, rats were given equivalent daily doses fractionated over 
various dosing intervals, including once, twice, three, or four times daily.46 Urinary 
kidney injury molecule-1 (KIM-1) was approximately tripled in the once and twice daily 
groups compared to the three and four times daily groups. In the same model, 
vancomycin AUC and Cmax were both moderately or strongly correlated with urinary 
KIM-1 and osteopontin.6  KIM-1 is a proximal tubule injury marker that has previously 
been shown to correlate with histopathologic damage of the proximal tubules in 
vancomycin induced kidney injury.121 Our group has studied KIM-1 in clinical AKI 
studies and shown that in critically ill patients with AKI, urinary KIM-1 is approximately 
two-fold higher 24-48 hours following AKI compared to critically ill patients without 
AKI with measures at ICU admission.161 We have also shown that KIM-1 is associated 
with the composite outcome of major adverse kidney events (death, renal replacement 
therapy, or reduced kidney function) out to six months.161 This knowledge of KIM-1’s 
behavior in clinically relevant AKI will also be useful in designing future studies 
incorporating urinary biomarkers of kidney injury between patients treated with 
continuous versus intermittent infusion.   
 In our systematic review and meta-analysis conducted in aim 4, one interesting 






typically carefully planned with nomograms, continuous infusions of vancomycin were 
often based on a flat dose of 30 mg/kg/day.70 This discrepancy in careful, deliberate 
dosing for one dosing strategy compared to a one-sized fits all approach for another 
strategy appeared to be at odds with evaluation of precise vancomycin dosing. To our 
knowledge, no cross-over study evaluating the clearance of vancomycin when 
administered continuously versus intermittently has been completed, thus while we 
assume that clearance is equivalent between the two dosing strategies based on principles 
of first-order elimination, the kidneys may handle vancomycin differently depending on 
the infusion strategy. Before we embark on future comparisons of continuous versus 
intermittent infusions of vancomycin, it seemed necessary to develop dosing schemes of 
continuous infusion vancomycin with the same level of effort that has been put into 
developing dosing schemes of intermittent infusion of vancomycin.  
7.5 Aim 5 
 In order to accomplish this, in aim 5 we studied 50 patients from the medical 
intensive care unit with 124 associated vancomycin serum concentrations and used 
dosing information obtained from clinical care to develop a population pharmacokinetic 
model for continuous infusion of vancomycin in this patient population. We successfully 
developed a one-compartment model to fit the data, parameterized by vancomycin 
clearance and volume. We observed significant covariate effects of BUN, weight, and 
age on vancomycin clearance that improved the fit of the model to the data, and 
compared and contrasted our model to others published using continuous infusion 
vancomycin in Chapter 6. We also derived important insights on the dosing of continuous 






maintenance dose and useful information on how the time interval from loading dose to 
maintenance dose initiation impacts the AUC during this time period. Our finding that 
delaying the initiation of the continuous infusion to 12 hours following the start of the 
loading dose is not only highly clinically relevant as outlined in Chapter 6, but it is also 
extremely useful for the design of future clinical studies testing continuous versus 
intermittent infusion. If the continuous infusion was required to be initiated shortly 
following the loading dose to not delay care, this would have made the design of a 
comparative effectiveness trial quite difficult given the short time interval for informed 
consent. However, by having this 12-hour window between the start of the next dose, 
when administered continuously or intermittently, the logistics of informed consent for 
such a trial become much more feasible.  
7.6 Strengths and Limitations  
When considered in totality, the five aims presented have considerable strengths, 
particularly their granular considerations of vancomycin doses and concentrations, 
sufficiently powered considering each study’s objective, and rapid ability to translate to 
clinical practice should a clinician or institution wish to adopt the particular strategies 
studied for precision dosing of vancomycin. While survey techniques and meta-analytic 
techniques have their own limitations, the primary limitation from our clinical data, 
particularly the pharmacokinetic data obtained in aims 3 and 5, is that they are derived 
from a single ICU in a single medical center. Other ICU populations may carry unique 
nuances, such as a higher incidence of augmented renal clearance or other 
pharmacokinetic alterations, compared with the medical ICU which is primarily a septic 






10 states in the country regarding obesity,163 which in concert with the single center 
nature may limit generalizability of these findings to other critically ill patients.  
7.7 Future Directions  
Critically ill patients have always represented a unique challenge for drugs with 
narrow therapeutic indices not only due to the presence of pharmacokinetic changes, but 
also the fluctuations that can occur in these patients from day-to-day that may influence 
pharmacokinetics. While we did not employ Bayesian forecasting in our aims, our data 
from aim 5 and the population pharmacokinetic model we have built serves as 
preliminary data to serve as priors in future Bayesian models for continuous infusions of 
vancomycin. For a more simplified approach, our simplified dosing nomogram developed 
also awaits further validation. While our data from aim 3 demonstrate that an intensive 
pharmacokinetic monitoring strategy following the first dose can improve AUC target 
attainment at steady state, we anticipate this approach certainly not applicable to every 
patient that receives vancomycin and the laborious nature may preclude adoption by 
many centers. In the future, if we are able to incorporate our model into a Bayesian 
forecasting system, potentially a single level following the initial dose will allow us to 
maximize precision dosing of continuous infusion vancomycin in critically ill patients. A 
number of other advancements on this front may also allow us to refine dosing 
predictions. First, serum creatinine is well-recognized as a poor predictor of renal 
function for dosing and assessing AKI, and this was confirmed in our population 
pharmacokinetic model where creatine clearance was poorly correlated with estimated 
parameters. Serum cystatin C has been shown to predict vancomycin troughs better than 






dosing estimates based on current renal function. Second, real-time glomerular filtration 
rate (GFR) assessment using fluorescent molecules allows for continuous monitoring of  
GFR which not only has implications for early detection of AKI, but also for potential to 
incorporate into precision dosing strategies.165 Microsampling techniques are also being 
developed that would minimize the invasiveness and labor associated with blood draws 
during therapeutic drug monitoring, which may allow for more frequent monitoring of 
vancomycin levels. In addition to the typical challenges of developing these technologies 
such as blood-plasma correlation, they need to be validated in critically ill patients 
specifically given shunted blood flow.166 
 While vancomycin stewardship is undoubtedly an important area of clinical focus 
to reduce unnecessary vancomycin exposure, our ability to optimize dosing for those who 
need it, particularly early in therapy, as well as protect the most vulnerable patients from 
further, significant kidney insults, demands that we optimize not only the dose and 
exposure, but the method of administration of vancomycin to minimize harm and 























































APPENDIX 2. First-Order Equations for Vancomycin Pharmacokinetic Calculations  
Patient-Specific Pharmacokinetic Parameters From First Dose 





  C1 = 1st random ~2 hours following completion of infusion 
   C2 = 2nd random ~12 hours following completion of infusion 
   T’ = time between C1 and C2 
 
2. Step 2: Calculate half-life (t1/2). 





3. Calculate Cmax: 
𝐶𝐶𝑚𝑚𝑚𝑚𝑚𝑚 =  
𝐶𝐶1
𝑒𝑒−𝑘𝑘(𝛥𝛥𝛥𝛥)
  C1 = 1st random ~2 hours following completion of infusion 
   ΔT = time between C1 and end of the infusion 
4. Calculate volume of distribution (Vd)   






 t= infusion time 
5. Calculate Clearance (Cl) 
𝐶𝐶𝐶𝐶 = 𝑘𝑘 𝑥𝑥 𝑉𝑉𝑑𝑑 
6. Calculate total daily dose (TDD) 







APPENDIX 2 (con) 
If not using first-dose kinetics: 
1.) k is estimated by using the creatinine clearance (CrCl) [Cockcroft-Gault or Salazar-
Corcoran if > 125% of ideal body weight] and the following equation: k = 0.00083 (CrCl) 
+ 0.0044 
2.) Vd is estimated using 0.7 L/kg based on actual body weight 
Calculating Intermittent Infusion 
1. Calculate Dosing Interval (τ) 
𝜏𝜏 =  
ln (𝐶𝐶𝑚𝑚𝑚𝑚𝑚𝑚,𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝐶𝐶𝑚𝑚𝑑𝑑𝐶𝐶,𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑)
𝑘𝑘
 + t  Cmax, desired: 40 mcg/mL 
    Cmin, desired: 10 mcg/mL 
    t = infusion time    






3. Calculate predicted Cmax based on MD and τ selected. 
𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑡𝑡𝑃𝑃𝑃𝑃 𝐶𝐶𝑚𝑚𝑚𝑚𝑚𝑚 =  
𝑀𝑀𝑇𝑇
𝑉𝑉𝑑𝑑
1 − 𝑃𝑃−𝑘𝑘 𝜏𝜏
 
4. Calculate predicted Cmin based on Predicted Cmax. 









APPENDIX 2 (con) 
Evaluating AUC of Intermittent Infusion at Steady State 
Step 1. Calculate k  







  T’ = Determined by subtracting the time difference b/t Cpk and Ctr 
from τ 
Step 2. Calculate half-life 




Step 3. Calculate Cmax and Cmin from Cpeak and Ctrough, respectively. 
𝐶𝐶𝑚𝑚𝑚𝑚𝑚𝑚 =  
𝐶𝐶𝑝𝑝𝑘𝑘
𝑒𝑒−𝑘𝑘𝑘𝑘′
  t’= time between Cpk as drawn and end of the infusion 
𝐶𝐶𝑚𝑚𝐿𝐿𝐿𝐿 =  𝐶𝐶𝑡𝑡𝑡𝑡 𝑥𝑥 𝑃𝑃−𝑘𝑘𝑡𝑡′ t’ = time between Ctr as drawn and true Cmin 







  t= infusion time in hours    
Step 5. Calculate Cl 
𝐶𝐶𝐶𝐶 = 𝑘𝑘 𝑥𝑥 𝑉𝑉𝑑𝑑 
Step 6. Calculate AUC  
𝐴𝐴𝐴𝐴𝐶𝐶𝐿𝐿𝐿𝐿𝑖𝑖𝑖𝑖𝐷𝐷𝐿𝐿𝐿𝐿𝐿𝐿 =  
(𝐶𝐶𝑚𝑚𝑚𝑚𝑚𝑚+𝐶𝐶𝑚𝑚𝑑𝑑𝐶𝐶)
2
𝑥𝑥 𝑡𝑡 t= infusion time  
𝐴𝐴𝐴𝐴𝐶𝐶𝑒𝑒𝑔𝑔𝐿𝐿𝑚𝑚𝐿𝐿𝐿𝐿𝑚𝑚𝑡𝑡𝐿𝐿𝐿𝐿𝐿𝐿 =  
 𝐶𝐶𝑚𝑚𝑚𝑚𝑚𝑚 −  𝐶𝐶𝑚𝑚𝐿𝐿𝐿𝐿
𝑘𝑘
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